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Curriculum vi tae i l l 
VOORWOORD 
Na de studies van Beex over "Klinische betekenis van de receptoractiviteit 
voor oestradiol in tumorweefsel van patiënten met een gemetastaseerd mam-
macarcinoom" (proefschrift KU, Nijmegen, 1979) en van Koenders over 
"Steroid hormone receptors in experimental and human mammary carcinoma" 
(proefschrift KU, Nijmegen, 1979) werd deze onderzoekslijn voortgezet, 
haar beslag krijgend in de totstandkoming van dit proefschrift. 
In het proefschrift van Koenders werd reeds een methodiek verantwoord 
voor de meting van de receptor-activiteit van progesteron, naast die voor 
oestradiol. McGuire e.a. suggereerden iimers dat tumoren, die hoofdzake-
lijk worden gevormd door cellen, die evenals normale doelwitcellen van 
oestradiol, nog het vermogen bezitten deze receptoren voor progesteron te 
synthetiseren, minder gededifferentieerd zouden zijn dan cellen met pro-
gesteron-receptor negatieve tumoren, die dit vermogen door verdere dedif-
ferentiatie zouden hebben verloren. De combinatie van metingen van recep-
tor-activiteit voor oestradiol én progesteron zou een betere voorspellende 
waarde hebben, met name voor het effect van endocriene behandelwijzen van 
patiënten met borstkanker, dan die voor oestradiol alleen. 
De in dit proefschrift gepresenteerde studies werden verricht bij pa-
tiënten met borstkanker, die op een aantal afdelingen van het Sint 
Radboudziekenhuis in verschillende fasen van hun ziekte worden behandeld. 
Daarom is dit proefschrift ook mede een resultaat van de werkgroep voor 
borstkanker, die thans in het Sint Radboudziekenhuis bestaat. Deze werk-
groep wordt gevormd door de volgende afdelingen: Endocriene Ziekten van de 
Kliniek voor Inwendige Ziekten, Experimentele en Chemische Endocrinologie, 
Chirurgie, Radiotherapie, Medische Oncologie van de Kliniek voor Inwendige 






I t is now generally accepted that about 50% of the patients with estradiol 
receptor posit ive (ER +ve) metastatic breast cancer respond with an ob-
jec t ive remission to hormonal treatment. Patients with estradiol receptor 
negative (ER -ve) tumors rare ly achieve an objective remission with these 
modes of therapy. Apparently, hormonal responsiveness of breast cancer, i f 
present, is res t r ic ted to those patients whose tumors have retained the 
biochemical machinery to synthesize receptor proteins for es t rad io l . In 
view of the considerable number of fa i lu res in predict ing hormonal res-
ponsiveness, there is need of a more re l iab le iden t i f i ca t ion of patients 
with hormone responsive tumors. 
F i r s t , i t has been suggested that the or ig ina l concept of estrogen ac-
t ion via the ER-pathway is not accurate (1) . According to the classical 
model, the estrogen receptor protein is located in the cytoplasm of the 
ce l l (2) . The ER assays current ly performed in most laborator ies, analyze 
the cytosol ic f rac t ion of tumor homogenates, not the ce l l nuc le i . A number 
of studies, including recent reports using immunohistochemical methods, 
indicate that the estrogen receptor protein is not located in the cyto-
plasm of the tumor ce l l but rather inside the nucleus (3-10). These f i nd -
ings have been recently reviewed (8,9,10) and are summarized in the f o l -
lowing. The nuclear estrogen receptor prote in , unoccupied by the hormone 
and readi ly extractable in low-ionic strength buf fers, leaks into the 
tumor cytosol during the homogenization procedure. This monomeric, cyto-
solic receptor protein sediments as a 4S-moiety when centrifuged in su-
crose gradients. In the low-ionic strength medium, th i s 4S-form of the 
receptor polymerizes to the tetrameric SS-form. This SS-form has been con-
sidered an artefact formed during the process of extract ion and homogeni-
zation of the tumor biopsy specimens. Apart from t h i s , there appears to be 
another receptor form located inside the nucleus which is extractable only 
in high-ionic strength mediums. This receptor form is not analyzed by the 
current ly used routine ER-assays. At present, the functional signif icance 
of th is form of the receptor is s t i l l obscure. A new model for estrogen 
action has been proposed. In the target ce l l a native 4S-receptor form is 
present located inside the nucleus and perhaps in equ i l ib r i im with small 
amounts of extranuclear receptor. This 4S-receptor with high a f f i n i t y for 
estradiol not so, however, for chromatin binds to the hormone. After 
the binding step, a temperature dependent act ivat ion process enro l ls , pro-
bably inside the nucleus, resul t ing in the t rans i t ion of the 4S-form to 
the dimeric 5S-form. This l a t t e r , act ivated, receptor form has high a f f i -
n i t y for chromatin and binds t i g h t l y to acceptor si tes of the genome re -
n 
suiting in the biological response. Probably, these modifications in the 
concept of estrogen action on target tissues, might have implications for 
the predictability of hormonal responsiveness of breast cancer as reflect-
ed in the biochemical ER assays. 
Secondly, it cannot be excluded that tumors with a high proportion of ER 
+ve cells and hence with higher concentrations of ER activity, are more 
likely to respond to hormonal treatment than tumors with low ER activity 
(11,12). 
Thirdly, it has to be realized that the reception of estradiol is only 
the first step in the complex pathway of the biological response to the 
hormone. Certain ER +ve tumors may not regress during hormonal treatment 
because of a defect in the pathway distal to the initial estrogen binding 
step. The group of McGuire advocated the measurement of a specific end-
product of estrogenic stimulation in order to determine hormonal respons-
iveness (13). Since the synthesis of the progesterone receptor protein 
(PgR) is estrogen dependent (14), these authors hypothesized that the PgR-
status of the tumor might be a more sensitive marker of hormonal responsi-
veness than the ER-status alone. Indeed, the initial findings from their 
institute showed that 13 out of 16 patients with ER +ve PgR +ve tumors 
responded with an objective remission to hormonal treatment compared to 
only 7 out of 17 patients with ER +ve PgR -ve tumors (15). In a first 
series of clinical observations, we found a similar trend (16,17). Several 
authors have reported data which supported these preliminary observations 
(18,19). Others have failed to demonstrate that the PgR-status adds to the 
predictive value of the ER-status (20,21). 
A final reason for discrepancy between hormone responsiveness and recep-
tor phenotype of the tumor, might be found in changes of the phenotype 
during the course of the disease due to dedifferentiation of the tumor. It 
is not excluded that tumors earlier characterized as receptor +ve and at 
that time hormone responsive, might be in a later stage of the disease, 
receptor -ve and than no longer responsive to hormonal treatment. In case 
of long intervals between the time of biopsy and the start of treatment, 
a change of the receptor phenotype might obscure the supposed relationship 
between receptor phenotype and hormonal responsiveness. 
In this thesis, we have first analyzed the distribution of the different 
receptor phenotypes and the quantitative receptor levels in various sub-
sets of patients in the course of the disease (Chapter 2 ) . 
In Chapter 3, we report on the consistency of ER and PgR activities in 
sequential biopsies in individual patients. 
In Chapter 4, we related the outcome of the analysis of PqR to the res-
ponse to hormonal treatment. 
Soon after the introduction of the ER assay. Knight et al (22) reported 
that the ER-status of the primary tumor is not only useful in predict ing 
hormonal responsiveness of metastatic disease, but in addition could pro-
vide information on the r isk of recurrence and on the length of the d is -
ease-free interval after treatment for the primary disease. These authors 
demonstrated that patients with ER +ve tumors had a s ign i f i can t l y lower 
r isk of recurrence and a longer relapse-free survival time than those with 
ER -ve tumors. The prognostic signif icance of the ER-status appeared to be 
independent of a number of other factors , e .g . , from patients with lymph-
node negative breast cancer those with ER +ve tumors had a longer relapse-
free survival than those with ER -ve tumors whereas a similar difference 
was found in lymph-node posi t ive breast cancer. In Chapter 5, we report 
two studies which disclose the impact of the length of the observation 
period on the resul ts of studies on the signif icance of prognostic fac-
to rs . 
Recently, Pichón et al (23) reported that the PgR-status of the primary 
tumor is an even more re l iab le predictor of recurrence than the ER a c t i -
v i t y . During the past f i ve years, a number of studies has been reported 
with often controversial results in th is respect. In Chapter 6, our own 
data on the prognostic signif icance of the PgR-status of the primary tumor 
are presented. 
In the f ina l chapter, we comment on a number of resul ts obtained in the 
previous chapters. 
REFERENCES 
1. Si i t e r i PK, Schwarz BE, Moriyama I , Ashby R, Linkie D, MacDonald PC: 
Estrogen binding in the rat and human. Receptors for reproductive hor-
mones. Adv Exp Med Biol 36, 97-112, 1973. 
2. Jensen EV, DeSombre ER, Jungblut PW: Estrogen receptors in hormone 
responsive tissues and tumors. In: Endogenous factors influencing 
host-tumor balance. (Eds) Wissler RW, Dao TL, Wood S, pp. 15-30. Uni-
vers i ty of Chicago Press, Chicago, 1967. 
3. Sheridan PJ, Buchanan JM, Anselmo VC, Martin PM: Equi l ibr ium: the 
in t race l lu la r d i s t r i bu t i on of steroid receptors. Nature 282, 579-582, 
1979. 
4. Schrader WT: New model for steroid hormone receptors? Nature 308, 17-
18, 1984. 
5. Welshons WV, Lieberman ME, Gorski J: Nuclear loca l izat ion of unoccu-
pied oestrogen receptors: cytochalasin enucleation of GH3 ce l l s . 
Nature 307, 747-749, 1984. 
6. King WJ, Greene GL: Monoclonal antibodies local ize oestrogen receptor 
in the nuclei of target ce l l s . Nature 307, 745-747, 1984. 
7. King WJ, DeSombre ER, Jensen EV, Greene GL: Comparison of immunocyto-
chemical and steroid-binding assays for estrogen receptor in human 
breast tumors. Cancer Res 45, 293-304, 1985. 
13 
8. Raemaekers JMM, Beex LVAM, Benraad ThJ: Steroidhormoon-receptoren en 
het mammae arc i noom. In: Het Medisch Jaar 1987 (Eds) ν Es JC, Joossens 
JV, Mandema E, Olthuis G, pp. 167-177. Bohn, Scheltema & Holkema, 
Utrecht/Antwerpen, 1987. 
9. Jensen EV, Greene GL, Closs LE, DeSombre ER, Nadji M: Receptors re­
considered: a 20-year perspective. Ree Prog Horm Res 38, 1-40, 1982. 
10. Gorski J , Welshons WV, Sakai 0, Hansen J , Walent J, Kassis J, Shull J , 
Stack G, Campen С: Evolution of a model of estrogen action. Ree Prog 
Horm Res 42, 297-329, 1986. 
11. Paridaens R, Sylvester RJ, Ferrazzi E, Legros Ν, Leclerq G, Heuson 
JC: Cl in ica l s ignif icance of the quant i tat ive assessment of estrogen 
receptors in advanced breast cancer. Cancer 46, 2889-2895, 1980. 
12. Beex LVAM, Koenders AJM. Is hormonal responsiveness in breast cancer 
age dependent? Rev Endocr Rel Cancer 19, 5-9, 1984. 
13. Horwitz KB, McGuire WL, Pearson OH, Segaloff A: Predicting response to 
endocrine therapy in human breast cancer: a hypothesis. Science 189, 
726-727, 1975. 
14. Horwitz KB, McGuire WL: Estrogen and progesterone: t h e i r relat ionship 
in hormone dependent breast cancer. In: Progesterone receptors in 
normal and neoplastic t issue. (Eds) McGuire WL, Raynaud JP, Baulieu 
ЕЕ, pp. 103-124, Raven Press, New York, 1977. 
15. McGuire WL, Horwitz KB, Pearson OH, Segaloff A: Current status of 
estrogen and progesterone receptors in breast cancer. Cancer 39, 2934-
2947, 1977. 
16. Beex LVAM: Klinische betekenis van de r e c e p t o r a c t i v i t e i t voor oestra-
d io l in tumorweefsel van patiënten met een gemetastaseerd mammacarci-
noom. Thesis, Nijmegen, 1979. 
17. Koenders AJM: Estradiol and progesterone receptors in experimental and 
human breast tumors. Thesis, Nijmegen, 1979. 
18. Dao TL, Nemoto T: Steroid receptors and response to endocrine abla-
t ions in women with metastatic cancer of the breast. Cancer 46, 2779-
2782, 1980. 
19. Young PCM, Ehrl ich CE, Einhorn LH: Relationship between steroid recep-
tors and response to endocrine therapy and cytotoxic chemotherapy in 
metastatic breast cancer. Cancer 46, 2961-2963, 1980. 
20. Manm' A, Arafah B, Pearson OH: Estrogen and progesterone receptors in 
the predict ion of response of breast cancer to endocrine therapy. 
Cancer 46, 2838-2841, 1980. 
21. Stewart J. King R, Hayward J, Rubens R: Estrogen and progesterone 
receptors: corre lat ion of response rates, s i te and timing of receptor 
analysis. Breast Cancer Res Treat 2, 243-251, 1982. 
22. Knight WA, Livingston RB, Gregory EJ, McGuire WL: Estrogen receptor: 
an independent prognostic factor for early recurrence in breast can-
cer. Cancer Res 37, 4669-4671, 1977. 
23. Pichón MF, Pal lud С, Brunet M, Milgrom E: Relationship of presence of 
progesterone receptors to prognosis in early breast cancer. Cancer Res 
40, 3357-3360, 1980. 
14 
Chapter 2 
ESTROGEN AND PROGESTERONE RECEPTOR ACTIVITIES IN HUMAN BREAST CANCER: DIS-
TRIBUTION OF THE PHENOTYPES AND ITS RELATION TO THE STAGE OF THE DISEASE, 
MENOPAUSAL STATE AND AGE 
Numerous reports in the literature deal with the frequencies of estrogen 
receptor (ER)-positivity in the various stages of breast cancer (1, for 
review). The data on the incidence of progesterone receptor (PgR)-positi-
vity are less exhaustive and recently reviewed by Hähne! (2). In this 
chapter, we report on the distribution of the different receptor pheno-
types in a rather large number of patients with primary breast cancer who 
were all detected and treated in our center. The clinical data of the 
majority of the patients are discussed in the following chapters of this 
thesis. 
In view of some recent studies (3,4,5), we related the qualitative as 
well as the quantitative ER- and PgR-status of the tumor to the menopausal 
state and the age of the patients. Furthermore, data are provided on the 
distribution of the receptor phenotypes in the course of the disease. 
PATIENTS AND METHODS 
The ER- and PgR-status were analysed both qualitatively as well as quanti-
tatively in the tumor tissue of 368 patients with primary breast cancer 
who were all detected and treated in our center in the period 1976 till 
1986. 
On the basis of the diameter of the primary tumor assessed by mammo-
graphie or histologic measurements (T-classification, UICC, 6) and the 
axillary lymph-node status at histologic examination on surgical tissue 
specimens (NQ = no lymph node involvement, N+ = lymph node metastases 
and N? = lymph node invasion unknown), the 368 patients were classified 
into three prognostic subgroups: 
i) patients with "good prognosis": T ^ N Q 
ii) patients with "poor prognosis": Τ3Τ4 irrespective of N 
or N+ irrespective of Τ 
iii) patients with "unknown prognosis": T1T2N? 
Patients were considered postmenopausal when menses had ceased for at 
least one year or after ovariectomy or when they were older than 55 years 
of age after previous hysterectomy. The two patients who were younger than 
55 years and underwent hysterectomy in the past, were classified as meno­
pausal state unknown. 
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The s t a t i s t i c a l comparisons between d i f f e r e n t subgroups of patients were 
made using Fisher's Chi Square test (P denoted by p) and Wilcoxon's two-
sample test (P denoted by p*). 
METHOD OF STEROID RECEPTOR ASSAY 
In the fo l lowing, a b r i e f out l ine of the procedure of the steroid-receptor 
assay current ly performed in our laboratory, is presented. 
The freshly excised tumor tissue is freed from fat and adjacent t issue. 
The biopsy specimen (preferably > 200 mg of tumor tissue) is immediately 
deep-frozen and stored u n t i l use at -196 0C in l i q u i d nitrogen. At the 
time of analysis (< 2 weeks after the biopsy was taken), the stored tissue 
is f i r s t pulverised in a stainless steel mortar immersed in l i q u i d n i t r o ­
gen. The resul t ing small pieces of tissue are then vibrated to a f ine pow­
der by means of a microdismembrator. Al l subsequent steps are performed at 
0-4 0 C . The powder is weighed and homogenised in cold phosphate buffer 
(weight/volume r a t i o 1:5). Following repeated aspiration and discharge 
through a Pasteur p i p e t t e , the buffer-t issue mixture is centrifuged at 
105.000 g for 60 minutes. The supernatant, called cytosol , is removed and 
analysed without delay. 
F i f t y m i c r o l i t e r s of cytosol are incubated with nine increasing concentra­
tions of t r i t i a t e d steroid at 4 0C in m i c r o t i t e r p l a t e s ; range of the con­
centrations between 0.5 χ 10"9M and 8 χ 10"^M (^H-oestradiol for the 
analysis of ER and Зн-02058 in the case of PgR analysis). The non-speci­
f i c binding is determined in the presence of 10"6M DES f o r the ER assay 
and 10"6M 02058 for the PgR-procedure. After equil ibrium is reached 
(18-20h incubation at 4 0 C ) , the unbound steroid is removed by adding 0.1 
ml DCC (dextran-coated charcoal) suspension. The m i c r o t i t e r p l a t e is shaken 
on a mechanical shaker for 10 minutes and centrifuged thereafter at 200 g 
for 20 minutes. Aliquots of 0.1 ml of the supernatants are transferred to 
counting v i a l s and the r a d i o a c t i v i t y is counted. 
The bound radioactv i ty (B) is subtracted from the t o t a l amount of radio­
a c t i v i t y present (T) giving the corresponding amount of unbound steroid (U 
= T-B). The r a t i o of the calculated non-specific binding (B n s ) and un­
bound steroid (U n s) is mult ip l ied by U giving the correct amount of non­
specif ic binding. The specif ic binding ( B s ) , for each of the nine ligand 
concentrations, can now be calculated according to the fol lowing equation: 
Bs = h o t - <u> JJÜ5-
uns 
The calculated Bs values are plotted against the corresponding Bs/U 
ratio's, according to Scatchard (7). After calculation of the line of best 
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fit by means of a weighed linear regression analysis, the number of speci­
fic binding sites is determined from the intercept on the abscissa and 
expressed in fmol/ml cytosol. The number of binding sites is divided by 
the protein concentration of the cytosol as determined according to the 
method of Lowry (8), giving the receptor amount expressed in fmol/mg pro­
tein. 
INTERPRETATION OF THE RESULTS OF THE STEROID-RECEPTOR ASSAYS 
Tumor specimens with a dissociation constant exceeding 2nM are considered 
to be devoid of specific binding sites and are classified as receptor 
negative. A protein concentration of 2 mg/ml cytosol is regarded as the 
lowest acceptable limit. 
This laboratory participates in an international inter!aboratory quality 
control program twice yearly (9). The interi aboratory quality control stu­
dies reveal that the variation coefficient for the analysis of the quanti­
tative ER-status is 7% and for that of the PgR-status 7.8% (10). 
As discussed in the thesis of Koenders (11), we initially regarded all 
tumor specimens with detectable specific binding sites as receptor posi­
tive. The lowest values actually measured were 5 and 7 fmol/mg protein for 
ER and PgR respectively. In a study from our institute on hormonal res­
ponsiveness of metastatic breast cancer, Beex and Koenders reported in 
1984 that patients with ER levels < 10 fmol/mg protein in their tumors 
rarely respond to hormonal treatment modalities (12). In accordance with 
these data, we now consider tumors as ER +ve only at ER levels exceeding 
10 fmol/mg protein. This cut-off value, in line with the experience in 
literature, is used in Chapters 4 and 6 as well as in the present chapter, 
since the respective studies were performed after 1984. With regard to the 
PgR-status, the same cut-off value of 10 fmol/mg protein is used, in keep­
ing with literature data (2). 
FREQUENCIES OF THE RECEPTOR PHENOTYPES 
























Table 1 shows that 68% of the 368 patients had an ER +ve tumor and 63% a 
PqR +ve tumor. Considering both receptor activities, the receptor pheno-
type ER +ve PgR +ve occurred most frequently (55%) whereas ER -ve PgR +ve 
tumors were found in only 9% of the patients. No activity of either re­
ceptor was detectable in 23% of the tumors and merely ER activity without 
PgR activity was detectable in 13% of the tumors. 
RECEPTOR PHENOTYPES RELATED TO THE TN-CLASSIFICATION 
Twenty-one patients (6%) had to be assigned to the group of patients with 
"unknown prognosis". The "poor prognosis"-group consisted of 220 patients 
and 127 belonged to the "good prognosis"-group. Table 2 shows that the 
frequencies of ER- and PgR-positivity did not differ significantly between 
the three prognostic subgroups (p>0.1, for both ER and PgR). The distribu­
tion of the different receptor phenotypes is presented in Table 3. No sig­
nificant differences were noted in the frequencies of the phenotypes be­
tween the prognostic subgroups. 
TABLE 2. RECEPTOR-STATUS RELATED TO THE TN-CLASSIFICATION. 
T1T2N0 
T3T4;N+ 
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- / - - / + 
η (%) η (%) 
34 (27) 10 (8) 
46 (21) 20 (9) 
6 (28) 2 (9) 
RECEPTOR PHENOTYPES RELATED TO MENOPAUSAL STATE AND AGE 
Fifty-five percent of the 366 patients whose menopausal state was known, 
were postmenopausal and 45% premenopausal. Table 4 shows that the post-
la 
menopausal patients had s i g n i f i c a n t l y more often ER +ve tumors than the 
premenopausal pat ients: 75% vs. 59% (p<0.005). In contrast, PgR-posit ivity 
was demonstrated more often in premenopausal pat ients, though with margin­
al signif icance: 70% vs. 58% in the postmenopausal group (p<0.05). 



















patients with menopausal state unknown are excluded (n=2). 
The d i s t r i b u t i o n of the four receptor phenotypes in pre- and postmeno­
pausal patients is presented in Table 5. The frequencies of the phenotype 
ER +ve PgR +ve as well as the phenotype ER -ve PgR -ve are equal in both 
groups. I t is of note that the phenotype ER +ve PgR -ve occurs more f r e ­
quently in postmenopausal patients whereas ER -ve PgR +ve tumors are a l ­
most exclusively found in premenopausal pat ients. 




















η . s . 
- / + 
η (%) 
30 (18) 
2 ( 1) 
< 0.0001 
patients with menopausal state unknown are excluded (n=2). 
Within the groups of pre- and postmenopausal pat ients, the d i s t r i b u t i o n 
of ER- and PqR-positivity was analysed according to decades of age (Table 
6 ) . The older premenopausal pat ients, i . e . , >40 years of age, had s i g n i f i ­
cantly more often ER +ve or PgR +ve tumors than the younger ones (p<0.05 
for ER and p<0.01 f o r PgR). In postmenopausal patients the frequency of 
ER-posit ivity increased with age up to 80% ER +ve tumors in the oldest age 
group. No such relat ionship was noted with regard to PgR-posit ivity. In 
f a c t , the higher percentages of PgR +ve tumors were found in the older 
premenopausal women. 
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TABLE 6. RECEPTOR-STATUS RELATED TO THE MENOPAUSAL STATE AND AGE. 
PREMENOPAUSAL 
< 40 years 
40 - 49 























p-value < 0.05 < 0.01 
POSTMENOPAUSAL 
40 - 49 
50 - 59 




















p-value n.s. n.s. 
QUANTITATIVE RECEPTOR ACTIVITIES 
The d i s t r i b u t i o n of the quanti tat ive receptor a c t i v i t i e s is i l l u s t r a t e d in 
Figures 1 and 2. The median ER level of the ER +ve tumors was higher in 
the group of postmenopausal patients than in the group of premenopausal 
women: 109 vs. 32 fmol/mg protein (p*<0.005). The median PgR levels did 
not d i f f e r s i g n i f i c a n t l y between the two menopausal groups: 100 fmol/mg 
protein before menopause and 93 fmol/mg protein after menopause (p*>0.1). 
No differences in the quantitat ive ER and PgR a c t i v i t i e s were found be­
tween the decades within the groups of pre- or postmenopausal pat ients. 
COMMENT 
I t is generally accepted that about 70% of the patients with primary 
breast cancer have ER +ve tumors, in keeping with our data (1). In the 
present analysis, PgR +ve tumors were found in 63% of the patients. L i t e ­
rature data on the incidence of PgR-positivity show a wide range varying 
from 17% to over 70% with a mean of 50% (2). There is no ready explanation 
for the apparent lack of consensus on the frequency of PgR-positivity but 
differences in tumor sample handling, receptor assay procedures and quite 
d i f f e r e n t d e f i n i t i o n s of receptor p o s i t i v i t y could at least in part ac-
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FIG. 1. 
Median ER levels of the 249 pa-
tients with ER +ve tumors related 
to aqe and menopausal state (the 
25% and 75% percentiles are 
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menopausal state unknown exclud­
ed). 
FIG. 2. 
Median PgR levels of the 232 
patients with PgR +ve tumors 
related to age and menopaus­
al state (the 25% and 75% 
percentiles are represented 
as о o; n=l with meno­
pausal state unknown exclud­
ed). 
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count for the disparate resul ts in various studies. Some of these factors 
are discussed extensively in several reports on the in ter - and int ra- labo-
ratory qua l i ty control programs (9,10,13,14). Our data on the frequency of 
PgR-posit iv i ty are in accordance with the resul ts of Thorpe et al (3) who 
uses the EORTC recommendations for the analysis of PgR a c t i v i t i e s , as we 
d id . 
Both ER and PgR were found to be posit ive in 55% of the tumors whereas 
no ac t i v i t y for ei ther receptor was detectable in 23%, in accordance with 
data of a number of recent reports (2,3,15,16). The receptor phenotype ER 
+ve PgR -ve was found predominantly after menopause. According to the 
hypothesis of Horwitz and McGuire (17), th i s phenotype re f lec ts the sub-
group of patients with ER +ve tumors who lack hormonal responsiveness. I t s 
c l i n i ca l signif icance w i l l be discussed in Chapter 4. PgR ac t i v i t y in the 
absence of detectable ER ac t i v i t y occurs in 18% of the premenopausal pa-
t ien ts and rarely after menopause. Sar i f f and Durant (18) reported that 
most of these tumors, do contain estrogen receptor ac t i v i t i es and th i s 
f inding is confirmed in our study on sequential biopsies (Chapter 3) . 
The frequency and quant i tat ive levels of ER +ve tumors are s ign i f i can t ly 
higher in postmenopausal patients than in premenopausal women. Further-
more, the incidence of ER-posi t iv i ty increases with advancing age, as re -
ported ear l ier (3,4,5,12,15,19). Postmenopausal patients with ER +ve 
tumors have higher median ER levels than the premenopausal pat ients, in 
keeping with previous observations (3,5,12,15,19). In contrast, a PgR +ve 
tumor is found predominantly in premenopausal patients though the d i f f e r -
ence in the frequencies of PgR-posit ivi ty between pre- and postmenopausal 
patients is only marginally s ign i f icant in accordance with the resul ts of 
others (2 ,3 ,5) . A straight relat ionship between decades and the frequen-
cies of PgR-posit iv i ty or the quanti tat ive PgR-status was not found in 
th i s analysis in support of the findings of Thorpe et al (3) and Fisher et 
al (4). These data contradict the results of Clark et al (5) who claim 
that the oldest premenopausal and the oldest postmenopausal patients have 
the higher median PgR levels. For a detailed discussion on the poorly 
understood mechanisms behind these dif ferences, we refer to the study of 
Clark et al (5) . 
Consistent with l i t e ra tu re data, we found no re la t ion between the d i f -
ferent receptor phenotypes and the d i s t r i bu t ion of the patients according 
to our modified TN-classi f icat ion (2 ,4 ,5) . Nevertheless, upon analysing 
the d i s t r i bu t ion of the d i f ferent phenotypes in a somewhat d i f ferent way, 
the frequency of receptor +ve tumors, especial ly PgR +ve tumors, can be 
shown to decrease with advancing disease. In a recent report from the 
Breast Cancer Study Group in th is hosp i ta l , Tinnemans et al compared thf 
incidence of the d i f fe rent receptor phenotypes in 4 groups of patients 
TABLE 7. RECEPTOR PHENOTYPES IN THE COURSE OF THE DISEASE. 
ER / PgR 
TT* TT- τ]-. гут" 
fo Jo Ht lo 
Non-palpable, o p e r a b l e 
pr imary breast cancer 52 71 13 8 8 
P a l p a b l e , operable 
p r i m a r y b r e a s t cancer 259 57 12 23 7 
(Tl-3. N0-2) 
P a l p a b l e , i n o p e r a b l e 
pr imary b r e a s t cancer 73 48 20 22 11 
(T4 or N3) 
First metastatic 
breast cancer 58 41 28 26 5 
More advanced* 
metastatic breast 92 28 28 42 2 
cancer 
•unpublished observations. The other data were derived from the study of 
Tinnemans et al (20). 
TABLE 8. RECEPTOR-STATUS IN THE COURSE OF THE DISEASE. 
ER+ PgR+ 
η % % 
Non-palpable, operable primary breast cancer 
Palpable, operable primary breast cancer 
Palpable, inoperable primary breast cancer 
F i rst metastatic breast cancer 
















(20): i ) patients with non-palpable, operable primary breast cancer who 
were detected by mammographie screening (n=52); i i ) patients with palpa­
b l e , operable primary breast cancer, i . e . , Т^.з No_2 (n=259); i i i ) pa­
t i e n t s with palpable, inoperable primary breast cancer, i . e . , T4 or N3 
(n=72) and iv) patients with metastatic disease whose receptor-status was 
analysed in tumor t issue obtained from the f i r s t recurrence, none of whom 
had received adjuvant systemic treatment in the past (n=58). We have ex­
tended these data with the resul ts of the receptor analyses in a group of 
92 patients with metastatic breast cancer whose receptor-status was meas­
ured in an even more advanced stage of the disease after a median period 
of 21 months after the appearance of the f i r s t metastases (mean ± s.d. 34 
+ 32, range 5-168 months). These patients had received a median number of 
3 systemic treatments (range 2-7) pr ior to the receptor analysis. The re­
sults are given in Tables 7 and 8. Table 7 c lear ly shows that the i n c i ­
dence of ER +ve PgR +ve tumors gradually decreased from 71% in the group 
of patients with non-palpable primary breast cancer to only 28% in the 
more advanced stages of metastatic disease (p<0.0001). On further analysis 
(Table 8 ) , i t appeared that the decline in PgR-posit ivity with advancing 
disease is almost twice as high as the decrease in ER-positiv1ty. 
These data might indicate that with progression of the disease hormonal 
responsiveness, as far as ref lected in steroid-receptor a c t i v i t i e s of the 
tumor t i s s u e , decreases. This cross-sectional argument for the loss of 
hormonal responsiveness with advancing disease is corroborated by data 
from sequential biopsies in individual patients which w i l l be presented in 
Chapter 3. These observations nicely i l l u s t r a t e common knowledge from 
c l i n i c a l experience. 
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Chapter 3 
CONCORDANCE AND DISCORDANCE OF ESTROGEN AND PROGESTERONE RECEPTOR CONTENT 
IN SEQUENTIAL BIOPSIES OF PATIENTS WITH ADVANCED BREAST CANCER: RELATION 
TO SURVIVAL 
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Pieters, Anthony G. Smals, Ttieo J. Benraad* and Peter W. Kloppenborg. 
Division of Endocrinology, Department of Medicine and *Divis ion of Experi-
mental and Chemical Endocrinology, University of Nijmegen, Nijmegen, "Піе 
Netherlands. 
ABSTRACT 
In 75 patients with advanced breast cancer, sequential biopsies 
were analyzed for estrogen receptor (ER). In 50 of these patients 
progesterone receptor (PgR) was also measured. Al l pairs of biop­
sies met the fol lowing c r i t e r i a : ( i ) interval between the two b i ­
opsies: at least 6 weeks ; ( i i ) biopsies performed at least б 
weeks after stopping endocrine therapy; and ( i i i ) concordant his­
tology. Discordance in ER was found in 14 of 75 patients (18.7%); 
PgR was discordant in 14 of 50 patients (28.0%). No s i g n i f i c a n t 
differences were found between concordant and discordant groups of 
patients in age at f i r s t diagnosis, menopausal s t a t e , diameter of 
the primary tumor, time interval between the two biopsies and i n ­
tervening therapy. The i n i t i a l ER level in patients whose ER 
changed from posit ive to negative was s i g n i f i c a n t l y lower than in 
patients whose ER remained posi t ive. PgR levels exhibited a r ise 
only when ER rose at the same time. Sequential assays have i n ­
creased the prognostic significance of ER and as a consequence the 
estimated survival time for patients whose tumors were ER-negative 
in both biopsies was s i g n i f i c a n t l y shorter than for patients whose 
tumors were ER-negative in only one of the two biopsies. We found 
no prognostic signif icance for PgR in either single measurements 
or repeated biopsies. 
Eur J Cancer Clin Oncol 20,1011-1018,1984 
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INTRODUCTION 
Measurement of estrogen receptor ac t i v i t y (ER) in tumor t issue of patients 
with breast cancer proves to be useful in selecting patients l i ke l y to 
respond to endocrine treatment. However, a posit ive ER assay does not 
guarantee a response to endocrine treatment since about 40% of these pa-
t ients f a i l to respond (1,2). 
At present i t is s t i l l controversial whether data about progesterone 
receptor a c t i v i t y (PgR) w i l l increase the p red ic tab i l i t y of the response 
to endocrine treatment (2-5) . The considerable number of fa i lures in pre-
d ic t ing the response to endocrine therapy could be due to inconsistency in 
the resul ts of sequential measurements of receptor a c t i v i t y for estradiol 
and progesterone. From the scarce data in the l i t e ra tu re i t becomes clear 
that changes in receptor status in the course of time have occurred in 
about 20% of subjects (6) . 
We measured ER and PgR sequentially in patients with advanced breast 
cancer and related these data to c l i n i ca l character is t ics and survival 
rates. 
MATERIALS AND METHODS 
Sequential ER assays were performed in 75 patients with loca l ly relapsed 
or advanced breast cancer, in 50 of whom PgR was also measured. Al l se-
quential biopsies met the following c r i t e r i a : ( i ) interval between the two 
biopsies: at least 6 weeks; ( i i ) biopsies performed at least 6 weeks after 
cessation of endocrine treatment; and ( i i i ) concordance in histology in 
the two biopsies. The major i ty of the patients (n=64) were under treatment 
in the breast c l i n i c of our hospi ta l . The case records of a l l patients 
were reviewed and c lass i f ied to ( i ) age at f i r s t diagnosis; ( i i ) menopau-
sal s tate; ( i i i ) diameter of the primary tumor; ( iv) s i te of biopsies; (v) 
histology; (v i ) intervening therapy; ( v i i ) time interval between the two 
biopsies; ( v i i ) disease-free in terva l ; and ( ix ) survival times. Patients 
were considered to be postmenopausal i f menses had ceased for at least 1 
yr or after ovariectomy was performed. In almost a l l patients the elevated 
levels of gonadotropins in blood samples supported th i s c lass i f i ca t ion . In 
10 of the patients surgery was the only therapy between the two biopsies; 
65 patients received ei ther radiotherapy alone (n=13), radiotherapy com-
bined with systemic treatment (n=37) or systemic treatment alone (n=15) 
between the two biopsies. I n i t i a l systemic treatment after metastases were 
detected included endocrine modalities (ovariectomy, tamoxifen or estro-
gens), endocrine treatment combined with chemotherapy (5-f luorouraci l and 
tamoxifen, or the la t te r in combination with 5 - f luorourac i l , methotrexate 
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and cyclophosphamide, CMF) or chemotherapy alone (CMF), fol lowing t rea t -
ment protocols. Later treatment modalities included aminoglutethimide, me-
droxyprogesterone acetate or the combination of adriamycin and cyclophos-
phamide. 
Survival times were reckoned from the date of f i r s t metastasis. One 
patient with an inoperable primary tumor but no distant metastases, whose 
sequential biopsies were taken from the primary tumor, was not included in 
th is analysis. The estimated survival functions were calculated by the 
method of Kaplan and Meier (7) , the differences between such functions 
being tested by Gehan and Mantel's non-parametric test (8,9) (P denoted by 
p*). Further s ta t i s t i ca l analyses were performed using Fisher's chi square 
test (P denoted by p) and Wilcoxon's two-sample test (P denoted by p**). 
Correlation coef f ic ients were calculated according to Spearman's rank non-
parametric analysis of variance (P denoted by p***). 
The receptor assays were performed using the dextran-coated charcoal 
method as described before (10). In our laboratory the lowest receptor 
values actual ly measured in human breast tumor cytosols were 5 and 7 
fmol/mg protein for ER and PgR respectively. 
Discordance in receptor status was defined as a qua l i ta t ive change from 
posit ive to negative or the reverse. 
RESULTS 
CLINICAL CHARACTERISTICS (Table 1) 
Table 1 shows that 14 out of 75 pairs of biopsies gave discordant resul ts 
for ER and 14 out of 50 pairs for PgR. There was no s t a t i s t i c a l l y s i g n i f i -
cant difference between patients with ER or PgR concordant and discordant 
biopsies in age at f i r s t diagnosis, menopausal state and diameter of the 
primary tumor. As might be expected, we found a s t a t i s t i c a l l y s ign i f icant 
re la t ion between the disease-free interval of patients whose f i r s t biopsy 
was taken from the primary tumor (n=46) and the interval between the two 
biopsies (r=0.6, P***<0.05). However, the time interval between the two 
biopsies did not d i f f e r s ign i f i can t ly between the groups of patients with 
concordant and discordant resul ts of ER or PgR. I t has to be noted that in 
the ER concordant group of patients s ign i f i can t l y more second biopsies 
were taken from lymph nodes than in the ER discordant group of patients 
(p<0.05). 
VARIABILITY IN RECEPTOR STATUS (Tables 2-4) 
In th is group of pat ients, 57.356 ER-positive (ER+) tumors and 46.0% PgR-
posit ive (PgR+) tumors were found at f i r s t biopsy (Table 2) . The table 
also shows the d i s t r i bu t i on of the various receptor phenotypes: ER+ PgR+, 
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TABLE 1. CLINICAL CHARACTERISTICS IN RELATION TO THE QUALITATIVE RESULTS 
OF SEQUENTIAL ER AND PgR ASSAYS. 
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* Including only those patients whose first biopsy was taken from the 
primary tumor. 
** Statistical significance (p<0.05) between the site of biopsy (lymph 
nodes) in the concordant and discordant ER groups. 
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38.0%; ER+ PgR-, 28.0%; ER- PgR-, 26.0%; and ER- PgR+, 8.0%. Table 3 shows 
the v a r i a b i l i t y of the receptor status during the course of the disease. 
As mentioned above, discordance in ER status was present in 14 out of 75 
patients (18.7%). In eight of them ER changed from posit ive to negative 
and in the renaining six patients the reserve was observed. With regard to 
the PgR status, the discordance rate was even higher: 14 of 50 patients 
(28.0%). In ten of these 14 patients PgR changed from posit ive to negative 
and in four from negative to posi t ive. Table 4 out l ines the consistency of 
the receptor phenotypes in sequential biopsies. Of the 23 i n i t i a l l y PgR-
posit ive tumors ten were negative at the second biopsy. Nine of these ten 
tumors were ER-positive at f i r s t biopsy and seven of these nine remained 
so, despite the change in PgR. Tlnus in the group of 19 patients with an 
ER+ PgR+ tumor at f i r s t biopsy, PgR became negative in nine tumors whereas 
ER changed in only two (p<0.05). Furthermore, i t appeared that the recep-
tor phenotype ER- PgR- was the most stable one: concordance 84.6%. Al l ER-
PgR+ tumors at f i r s t biopsy (n=4) changed the i r phenotype at second biop-
sy. Three of these tumors changed to ER+ PgR+. 
QUANTITATIVE CHANGES IN ER AND PgR (Figs 1-3) 
In F ig . l the absolute values of ER at f i r s t biopsy are depicted. The me-
dian ER value of the 43 ER-positive tumors at f i r s t biopsy was 60 fmol/mg 
prote in. At second biopsy 35 of these tumors ranained ER-positive. The 
median ER value at f i r s t biopsy of th i s group of patients was about equal, 
71 fmol/mg protein. The mean ER value at f i r s t biopsy of the remaining 
eight pat ients, whose tumor became ER-negative at second biopsy, was sig-
n i f i c a n t l y lower than the mean ER value of the tumors which remained ER-
posi t ive (44.5 ± 29.4 vs. 191.9 ± 275.4 fmol/mg protein respect ively, 
p**<0.05). Such a dif ference could not be established for PgR, as shown in 
Fig.2: the median PgR value of the 23 PgR-positive tumors at f i r s t biopsy 
was 51 fmol/mg prote in; 13 of these patients remained PgR-positive at 
second biopsy, with an i n i t i a l l y median PgR value of 74 fmol/mg prote in; 
there was no s t a t i s t i c a l l y s ign i f icant dif ference between the mean PgR 
value at f i r s t biopsy of the ten patients whose timor became PgR-negative 
at second biopsy and the mean PgR value of the 13 tumors that remained 
PgR-positive (86.5 ± 140 vs. 138.1 ± 151 fmol/mg protein respect ively, 
p**>0.1). 
With regard to those tumors whose ER or PgR status remained pos i t ive , 
the median values of ER or PgR at f i r s t and second biopsy were about 
equal: for ER 71 and 62 fmol/mg protein respect ively; for PgR 74 and 45 
fmol/mg protein respect ively. Figure 3 shows the re la t ion between the 
changes in absolute ER values (AER) and the changes in absolute PgR values 
(APgR). When PgR increases, ER r ises concomitantly. When ER decreases, PgR 
f a l l s at the same time. 
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(η=θ) (n-35) 
p**<0.05 
FIG. 1. Absolute ER levels of a l l patients with ER-positive timors at 
f i r s t biopsy (n=43), of those whose ER status remained posit ive (n=35) and 
of those whose ER status became negative (n=8) at second biopsy. 
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PgR pos I o biopsy 
(n=23) 
PgR pos-»neg PgR p o s - » p o s 
(n=10) (n=13) 
p**>0.1 
FIG. 2. Absolute PgR levels of a l l patients with PgR-positive tumors at 
f i r s t biopsy (n=23), of those whose PgR status remained posit ive (n=13) 
and of those whose PqR status became negative (n=10) at second biopsy. 
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FIG. 3. Relation between the changes in absolute ER levels (AER) and ab­
solute PgR levels (APgR) in sequential biopsies (n=39). The patients with 
ER-PgR-tumors at both biopsies (n= l l ) are not included in th is f i g u r e . 
SURVIVAL ANO ER AND PgR STATUS (Figs 4-7) 
Fig.4 shows the estimated survival time of the patients with ER-positive 
tumors, which is s i g n i f i c a n t l y longer than of those with ER-negative t u ­
mors (p* < 0.001). The survival curves were related to the receptor status 
in the f i r s t biopsy specimen. There was no s i g n i f i c a n t difference in e s t i ­
mated survival times between groups of patients with PgR-positive and PgR-
negative tumors at f i r s t biopsy (Fig.5). 
TOO 1 2 0 
S u r v i v a l ( m o n t h s ) 
FIG. 4. Estimated survival times of the patients with ER-positive (n=43) 
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S u r v i v a l ( m o n t h s ) 
FIG. 5. Estimated survival times of the patients with PgR-positive (n=23) 
or PgR-negative (n=26) tumors at f i r s t biopsy. 
Sur· 
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FIG. 6. Estimated survival times of the patients with ER+ PgR+ (n=19), 
ER+ PgR-, (n=14) or ER- PgR- (n=12) tumors at first biopsy. 
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With regard to both ER and PgR at f i r s t biopsy. Fig.6 shows that patients 
with ER+ PgR+ tumors survived s i g n i f i c a n t l y longer than patients with ER-
PgR- tumors (p*<0.02). As expected, patients with ER+ PgR- tumors showed 
survival functions similar to those with ER+ PgR+ tumors (p*>0.1). Fig.7 
shows that patients with ER-negative tumors in both biopsies had a s t a t i s ­
t i c a l l y s i g n i f i c a n t l y shorter estimated survival time than patients with 
one ER-negative and one ER-positive tumor in the biopsies (p*<0.02). The 
25 patients with ER-negative tumors in both biopsies had an extremely 
short estimated survival time: half of these patients were expected to die 
within 18 months after f i r s t metastasis. With regard to the four PgR phe-
notypes at repeated biopsies (pos •*• pos, pos -»• neg, neg •* neg, neg •» pos), 
no s t a t i s t i c a l l y s ign i f icant differences were found in the respective 
estimated survival functions. 
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FIG. 7. Estimated survival times of the patients with ER-negative tumors 
at both biopsies (n=25) and those with only one ER-negative tumor in the 
two biopsies (n=14). 
DISCUSSION 
The data obtained in t h i s study indicate a discordance rate for ER in se­
quential biopsies of patients with advanced breast cancer of 18.7%. Hull 
et al.(11) reported a discordance rate for ER of 16.5*. As stated by Lee 
(6) in her review of the l i t e r a t u r e , most authors reported a more frequent 
change from ER-positive to ER-negative than the opposite. Several factors 
contr ibute to the v a r i a b i l i t y of the ER status during the course of the 
disease. Rosen et a l . (12) and Webster et a l . (13) stated that the longer 
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the time interval between the two biopsies, the more l i ke l y a discordant 
result w i l l be obtained from the second biopsy. Our resul ts and those of 
Hull et a l . (11) and Paridaens et al .(14) contrast with these f indings. 
Hull et al.(11) reported that a change in ER status from ER-negative to 
ER-positive was more frequently found in patients with primary tumors of 
less than 2 cm than in patients with larger primary tumors. They suggest 
that tissue sampling errors were made at f i r s t biopsy. In our study there 
was no s t a t i s t i c a l l y s igni f icant difference in size of the primary tumor 
between the ER-discordant and -concordant groups of pat ients. Neverthe-
less, one is forced to admit that the number of very small primary tumors 
in our study was too small to exclude the poss ib i l i t y that tissue sampling 
errors may play an important role in the v a r i a b i l i t y of the receptor sta-
tus. In the group of patients with ER-concordant resu l ts , s ign i f i can t l y 
more second biopsies were taken from lymph nodes than in the ER-discordant 
group. This f inding so far remains unexplained. With regard to intervening 
therapy between the two biopsies, i t has to be noted that in f ive of the 
eight patients whose tumor ER status changed from posi t ive to negative, 
inst i tu ted tamoxifen treatment was withdrawn 6 weeks before the second b i -
opsy was performed. I f we exclude these pat ients, the discordance rate for 
ER was 12.8% (9/70). Both our own and Hul l 's observation (11) can be ex-
plained by the f indings of Fabian et a l . ( 15 ) , who reported that blood ta-
moxifen levels were s t i l l detectable 6 weeks after stopping th is therapy. 
With regard to the absolute ER levels at f i r s t biopsy, we found that ER 
values at f i r s t biopsy were s ign i f i can t ly lower in the groups of patients 
whose ER status became negative at second biopsy than in those whose ER 
status remained posi t ive. King et a l . (3) reported similar f indings, where-
as Webster et al .(13) were unable to demonstrate such a difference in i n i -
t i a l ER values. 
L i terature data concerning the v a r i a b i l i t y of PgR are scarce. The d is-
cordance rate of PgR status in th is series was even higher than in the ER 
status: 28.0%. Matsumoto et al.(16) reported a discordance rate for PgR of 
22.2% and King et a l . (3) found a discordance of 28.0%. In the f i r s t report 
from our laboratory Koenders et al.(17) reported a change in PgR status in 
30.0% of the pat ients. Based upon our own findings and the l i te ra tu re 
data, we draw the conclusion that ER a c t i v i t y of tumor tissue is a more 
stable feature than PgR ac t i v i t y . This considerable v a r i a b i l i t y of PgR in 
the course of time undermines the value of PgR for the predict ion of re-
sponses to endocrine therapy. 
The reproduc ib i l i t y of ER and PgR analyses in our laboratory is high. An 
intralaboratory control led study, recently updated by Koenders and Benraad 
(18), showed a within-run var iat ion coef f ic ient of 7.0% for ER and 7.8% 
for PgR. That i s , i f ER and PgR analysis in a given tumor specimen are 
repeated on the same day, the var iat ion coef f ic ient for absolute ER and 
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PgR values in the tumor cytosol is 7.0 and 7.8% for ER and PgR respective­
ly . Koenders et al.(17) reported ear l ier that simultaneously taken biopsy 
specismens from various tumor sites showed a concordance rate of 92.0% for 
ER (11 out of 12 cases) and of 100% for PgR (7 out of 7 cases). 
According to the hypothesis of Horwitz et a l . ( 1 9 ) , the presence of PgR 
in tumor t issue r e f l e c t s an intact ER pathway. In general the correlat ion 
between ER and PgR is not very close (2) . Our analysis of quantitat ive re­
ceptor levels in sequential biopsies supports t h i s theory: i n i t i a l l y PqR-
posit ive tumors exhibited a r ise in PgR value in subsequent biopsies only 
when ER rose at the same time. Furthermore, i t was shown that whenever ER 
levels declined in mult ip le biopsies, PgR f e l l concomitantly, and that the 
receptor phenotype ER- PgR+ showed discordance in a l l four cases studied. 
We found no data in l i t e r a t u r e dealing with the prognostic signif icance 
of repeated receptor measurements in patients with advanced breast can­
cer. Estrogen receptor a c t i v i t y is generally considered an independent 
prognostic factor in breast cancer (1,2), whereas the data in l i t e r a t u r e 
concerning PgR in t h i s respect are at least controversial (2,20-25). Our 
resul ts strongly support the significance of ER as a prognostic factor in 
patients with advanced breast cancer. Even those patients whose tumor t i s ­
sue only once contained ER had a s i g n i f i c a n t l y longer estimated survival 
time than patients with two ER-negative tumors at sequential biopsies. The 
super ior i ty of PgR compared with ER in predict ing survival times could not 
be established either as a single factor or in combination with ER. We 
therefore conclude that sequential ER assays w i l l increase the prognostic 
signif icance of t h i s receptor. The determination of PgR a c t i v i t y , once or 
twice, does not add to the prognostic signif icance of ER. 
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ABSTRACT 
The predict ive value of the progesterone receptor a c t i v i t y (PgR) 
was studied in a group of 84 patients with estradiol receptor (ER) 
posit ive advanced breast cancer who received their f i r s t endocrine 
treatment (tamoxifen or ovariectomy), with special emphasis on the 
timing of the receptor analysis. Al l patients were treated at one 
center and receptor analyses performed in one laboratory. In the 
group of 27 patients with PgR analysis performed immediately prior 
to the s tar t of treatment, 14 out of 18 PgR+ve and only 2 out of 9 
PgR-ve patients responded (p<0.02). In contrast, when PgR was ana-
lysed > 6 months prior to the s tar t of treatment, the response 
rates for PgR+ve and PgR-ve patients did not d i f f e r s i gn i f i can t l y : 
55% vs. 33% respect ively. With regard to quant i tat ive rather than 
qual i ta t ive PgR data, PgR levels exceeding 100 fmol/mg protein i r -
respective of ER levels, are an excellent indicator of hormonal 
responsiveness with a response rate of more than 80%, even i f PgR 
analyses are performed long before the s tar t of treatment. 
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INTRODUCTION 
There is s t i l l no consensus whether measurement of the progesterone recep-
tor a c t i v i t y (PgR) in tumor tissue adds to the p red ic tab i l i t y of hormonal 
responsiveness of advanced breast cancer as assessed by measuring the 
estradiol receptor ac t i v i t y (ER). By combining the data of 14 studies, 
Sedlacek and Horwitz (1) showed that patients with ER+ve PgR+ve tumors 
w i l l respond to endocrine therapy in about 70% of the cases whereas the 
patients with ER+ve PgR-ve tumors do so in about 30%. The response rates 
in the individual studies varied considerably and several authors found no 
additional predict ive value for PgR compared to ER alone (2-5). Recent 
work in several laboratories including ours, indicate that the predict ive 
value of PgR might be hampered by the considerable inconsistency of PgR 
when analysed sequential ly in the course of the disease (6-9). Stewart et 
a l . (4) suggested that the analysis of PgR is only useful when carried out 
immediately before the s tar t of treatment. However, the subgroups of pa-
t ien ts in the i r study d i f fered s ign i f i can t l y in several prognostic v a r i -
ables ( i . e . age, menopausal state, disease-free i n te rva l , s i te of metasta-
s i s ) . Therefore, the authors themselves stated that f i rm conclusions could 
not be drawn. We restudied the c l i n i ca l usefulness of the qual i ta t ive PgR 
analysis in predict ing hormonal responsiveness in a group of patients with 
ER+ve advanced breast cancer. Special attent ion was paid to the interval 
between the PgR analysis and the star t of the endocrine treatment. Fur-
thermore, since the d is t inc t ion between receptor p o s i t i v i t y and negat iv i ty 
is a s impl i f i ca t ion of the continuous variable that receptor concentration 
rea l l y i s , we addi t ional ly examined whether quant i tat ive PgR data is a 
better indicator than the merely Quali tat ive PgR status, as was establ ish-
ed ear l ier for ER by Paridaens et a l . (10) . 
PATIENTS AND METHODS 
PgR was analysed in tumor specimens of 84 patients with ER+ve breast can-
cer. Al l patients received their f i r s t endocrine therapy and were treated 
at our breast c l i n i c by the same physicians. The resul ts of ER and PgR 
analyses were available before the star t of the endocrine treatment. 
Twenty-one of the 84 patients had received pr ior adjuvant chemotherapy (a 
combination of cyclophosphamide, methotrexate and 5- f luorourac i l ) . The 
f i r s t endocrine therapy was either tamoxifen (20 mg ora l l y twice da i l y : 
premenopausal n=3, postmenopausal n=68) or surgical oophorectomy (premeno-
pausal n=13). Before the s tar t of the endocrine therapy a l l patients had a 
f u l l physical examination with measurements and/or photographs of v i s ib le 
lesions, complete blood counts and biochemical screening, a chest X-ray, a 
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bone scan and radiographs of the areas with increased uptake. Liver scans 
or upper abdominal echographic exeminations were performed only i f l i ve r 
metastases were suspected c l i n i c a l l y and/or biochemically. Patients were 
followed at the out-pat ient c l i n i c at regular in terva ls , usually monthly. 
Al l patients were evaluated for the response to the treatment three 
months after the s tar t of the therapy. The response to the endocrine 
treatment was assessed, always by the same physician and an experienced 
rontgenologist, according to the U. I .C .C. -c r i te r ia (11). The patients 
whose tumors showed neither an objective remission nor a fa i l u re to the 
treatment, were considered to have stable disease and are included in the 
analysis as "no-remission". After more prolonged observation periods these 
patients were reassessed. One patient had progressive disease af ter 4 
months of therapy, whereas the remaining 4 patients were s t i l l c lass i f ied 
as having stable disease after reassessment (duration of stable disease 
being 7, 8, 13 and 42 months respect ively) . Patients with non-assessable 
lesions (such as pleural ef fus ions) , whether or not other assessable l e -
sions were present, were considered not évaluable and as a consequence ex-
cluded from th is study. 
The menopausal state was defined as postmenopausal when menses had 
ceased for at least 12 months or when ovariectomy had been performed 
ear l ie r . 
The ER and PgR assays were a l l performed in the same laboratory on h i s -
to log ica l l y proven breast cancer tissue using the dextran-coated charcoal 
method with mul t ip le-point Scatchard-plot analysis, as described ear l i e r 
(12). Levels > 10 fmol/mg protein were considered receptor posi t ive (both 
ER and PgR) (dissociat ion constant KQ < 2nM). For a l l the assays the 
minimum cytosol protein concentration was 2 mg/ml cytosol. 
S ta t is t i ca l analysis was performed using Fisher's Chi Square test (P de-
noted by p) and Wilcoxon's two sample test (P denoted by p*). 
RESULTS 
QUALITATIVE PgR DATA AND THE RESPONSE TO THE FIRST ENDOCRINE TREATMENT 
In the group of 84 patients with ER+ve advanced breast cancer, 52 patients 
{62%) had a PgR+ve tumor whereas the remaining 32 patients (38%) lacked 
PgR in the i r tumor t issue. Forty-one out of the 84 patients (49%) showed 
an objective remission to the f i r s t endocrine therapy. Five patients had 
stable disease and the remaining 38 patients had progressive disease 
during the therapy. Table 1 shows the c l i n i ca l character ist ics of both 
groups. The qua l i ta t ive PgR status of the tumor was the only s ign i f icant 
discriminant between both groups: about 60% of the PgR+ve patients showed 
an objective remission versus 31% of the PgR-ve patients (p<0.02). 
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TABLE 1. CLINICAL CHARACTERISTICS OF THE 84 PATIENTS WITH ER+ve ADVANCED 
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TABLE 2. CLINICAL CHARACTERISTICS OF THE 84 PATIENTS WITH ER+ve ADVANCED 
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Table 2 i l l u s t r a t e s that there were no imbalances in the c l i n i c a l cha­
r a c t e r i s t i c s between the patients with PgR+ve and PgR-ve tunors. 
TABLE 3. TIMING OF RECEPTOR ANALYSIS AND THE RESPONSE TO THE FIRST ENDO­
CRINE TREATMENT. 
ER+ PgR+ ER+ PgR- Al l 
n=52 n=32 n=84 
remissions/totals remissions/totals remissions/totals 
Immediately pr ior 14/18 p<0.02 2/9 16/27 
1 - 6 months pr ior 2/7 n.s. 2/5 4/12 
> 6 months pr ior 15/27 n.s. 6/18 21/45 
Table 3 shows the data on the response to the treatment related to the 
timing of the PgR analysis. When PgR was analysed immediately pr ior to the 
start of the treatment, 78% of the patients with ER+ve PgR+ve tumors res­
ponded whereas only 22% of the patients with ER+ve PgR-ve tumors showed an 
objective remission (p<0.02). In contrast, when the interval between the 
PgR analysis and the start of the treatment exceeded 6 months, the PqR-
status did not add to the predictive value of ER (p>0.1). In these sub­
groups of patients no s ign i f icant differences were noted between the 
PgR+ve and PgR-ve patients in any of the c l i n i c a l character ist ics (data 
not shown). Table 3 further shows that a similar impact of the timing of 
the receptor analysis was not found for ER. When the 21 patients who re­
ceived pr ior adjuvant chemotherapy were excluded from t h i s analysis, simi­
lar data were obtained: in the "inmediately-prior"-group 91% (10/11) of 
the ER+ve PgR+ve patients and 28% (2/7) of the ER+ve PgR-ve patients res­
ponded (p<0.03) whereas in the " > 6 months-prior"-group no s ign i f icant 
difference was found between the PgR+ve and PgR-ve pat ients: 13 out of 22 
responded in the former versus 6 out of 12 in the l a t t e r (p>0.1). 
QUANTITATIVE PgR DATA AND THE RESPONSE TO THE FIRST ENDOCRINE TREATMENT 
Table 4 shows the c l i n i c a l character ist ics of the 27 patients with ER+ve 
PgR+ve tumors with PgR analyses performed > б months pr ior to the start of 
treatment. I t appeared that the quant i tat ive PgR levels were the only s i g ­
n i f i c a n t discriminant between the responders and the non-responders: the 
mean PgR level for the former was 295 fmol/mg protein and for the l a t t e r 
87 fmol/mg protein (p*<0.02). F i g . l shows the individual ER and PgR levels 
of the responding and non-responding pat ients. At PgR levels > 100 fmol/mg 
45 



























remission no remission remission no remission 
n=21 n = 24 η =15 n=12 
FIG. 1. Quantitative ER and PgR data and the response to the f i r s t endo­
crine treatment. All receptor analyses performed > 6 months prior to the 
s t a r t of the treatment. 
protein the number of patients with an objective remission was s i g n i f i ­
cant ly higher than at the lower levels: 83% (10/12) vs. 33% (5/15) res­
pectively (p<0.04). At PgR levels > 300 fmol/mg protein a l l patients re­
sponded. Due to the overlap in the quant i tat ive ER data, the discrimina­
t i o n between responding and non-responding patients was not possible by 
regarding the ER levels. 
Fig. 2 i l l u s t r a t e s the impact of combining quanti tat ive ER and PgR 
data. Qjant i ta t ive PgR data proved to be superior to the quantitat ive ER 
data in predict ing the response: at PgR levels exceeding 100 fmol/mg pro­
t e i n 10 out of 12 patients responded irrespect ive of the quanti tat ive ER 
levels whereas only 1 out of б patients with PgR levels < 100 fmol/mg pro­
te in but ER levels > 100 fmol/mg protein responded (p<0.03). The numbers 
of patients in the groups with PgR analyses performed immediatelν pr ior or 
between 1 and 6 months pr ior to the start of the treatment, were too small 
to permit a s t a t i s t i c a l analysis. 
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TABLE 4. CLINICAL CHARACTERISTICS OF THE PATIENTS WITH PgR ANALYSIS PER­
FORMED > 6 MONTHS PRIOR TO THE START OF THE FIRST ENDOCRINE 
TREATMENT. 
REMISSION NO REMISSION 
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The present study c lear ly demonstrates that both the qua l i ta t ive as well 
as the quant i tat ive analysis of PgR s ign i f i can t l y improves the predictabi -
l i t y of hormonal responsiveness in patients with ER+ve advanced breast 
cancer. When the qua l i ta t ive PgR status of the tumor is assessed immedia-
te ly pr ior to the s tar t of the f i r s t endocrine treatment, 78% of the pa-
t ients with ER+ve PgR+ve tunors show an objective remission whereas only 
22% of the patients with ER+ve PgR-ve tumors respond. In contrast, PgR 
does not add to the predict ive value of ER when PgR analysis is performed 
> 6 months prior to the s tar t of the treatment. 
Roughly, these resul ts reconfirm the preliminary suggestions of Stewart 
et a l (4 ) . I t has to be noted that unlike the i r study, no imbalances in 
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FIG. Ζ. Combined quant i tat ive ER and PgR data and the response to the 
f i r s t endocrine treatment. Al l receptor analyses performed > б months 
pr ior to the start of the treatment. ( · = objective remission; о = no re­
mission). 
noted. Since tumor t issue is not infrequently inaccessible for performing 
a biopsy with analysis of PgR, we took special interest in the predict ive 
value of quant i tat ive rather than the merely q u a l i t a t i v e PgR data in the 
group of patients with PgR analysis performed > 6 months prior to the 
s tar t of treatment. Our data c lear ly show that PgR levels > 100 fmol/mg 
protein are an excellent indicator of hormonal responsiveness with an ex­
pected response rate of more than 80%. Furthermore, the quantitat ive PgR 
data proves to be superior to the quant i tat ive ER data as i l l u s t r a t e d by 
our f inding that given a PgR level > 100 fmol/mg protein 85% of the pa­
t i e n t s show an objective remission, i rrespect ive of the ER levels. 
Several reports, including ours, indicate that about 40 to 50% of the 
i n i t i a l l y PgR+ve tumors become PgR-ve in analyses of subsequent biopsies 
whereas about 15% show the reverse change in PgR status (6-9). In view of 
t h i s considerable inconsistency of the PgR status the present data on the 
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predictive value of PgR is not too unexpected. For ER a suchlike high dis-
cordance rate has not been established (6,7,8,13) indicating that the pre-
dictive value of ER will not be affected by the timing of the ER analysis 
as confirmed in this study. From the data on the quantitative PgR analysis 
we hypothesize that tumors with initially low PgR levels are more liable 
to become PgR negative in subsequent biopsies than the tumors with the 
higher PgR levels. In the study of Harland et al.(7) as well as in ours 
(8) the PgR levels in the tumors changing from positive to negative were 
generally lower than those in the tumors which remained PgR+ve. 
Apart from the interval between the biopsy and the start of the endo-
crine treatment, other factors may have contributed to the outcome of this 
study. One might wonder whether the predictive value of the PgR status as 
assessed in metastatic tumor tissue differs from that obtained in the pri-
maries. However, we did not find any difference in the frequencies of 
either primary tumors nor metastases as the source of tissue analysed be-
tween the several subgroups of patients. Patients with visceral metastases 
are more likely to lack accessible tumor tissue for PgR analysis immedia-
tely prior to the start of the treatment and thus could have been over-
represented in the group of patients with PgR analysis performed > 6 
months prior to the start of the treatment. In that case lower response 
rates would have been expected merely because of the lower response rates 
to endocrine therapies in patients with visceral metastases. However, no 
such imbalance was noted in our study. 
In conclusion, the clinical usefulness of PgR in the management of ad-
vanced breast cancer has to be reappraised in view of the findings pre-
sented in this study. The qualitative PgR status of ER+ve breast cancer 
tissue contributes significantly to the predictability of the outcome of 
the first endocrine treatment only when PgR is analysed immediately prior 
to the start of such therapy. Whenever tumor tissue is inaccessible to 
perform a biopsy with PgR analysis, the quantitative rather than the qual-
itative PgR results of a former biopsy permit a better prediction of hor-
monal responsiveness than the quantitative ER data. 
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Chapter S 
PROGNOSTIC SIGNIFICANCE OF ESTROGEN RECEPTOR ACTIVITY IN PATIENTS WITH 
PRIMARY BREAST CANCER 
In th is Chapter, two studies are presented on the prognostic signif icance 
of estrogen receptor ac t i v i t y in the same group of patients who where 
treated for primary breast cancer in the period 1974 t i l l 1981. 
The studies d i f f e r in the length of fol low-up: the f i r s t paper, published 
in the Nederlands T i j dsch r i f t voor Geneeskunde, with a median duration of 
observation of 34 months and the second, published in 1985, with a median 
follow-up of 76 months. In the la t te r study, one of the 176 patients was 
excluded from the analysis because of the development of metastases of 
three d i f fe rent primary tumors, a l l detected during the observation 
period. In the f i r s t study, with the shorter fo l low-up, we found in ac-
cordance with l i t e r a t u r e data at that t ime, that patients with ER +ve t u -
mors had a s ign i f i can t l y lower r isk of recurrence than the i r ER -ve coun-
terpar ts . In the second study, with the longer fol low-up, th i s dif ference 
had disappeared. 
The two studies together i l l u s t r a te that in a malignancy in which meta-
stases may appear even as late as 15 to 20 years after the i n i t i a l diag-
nosis, conclusions on the signif icance of prognostic factors should not be 
drawn when based upon short-term follow-up studies. 
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5.1 DE PROGNOSTISCHE BETEKENIS VAN ONDERZOEK NAAR RECEPTORACTIVITEIT VOOR 
ESTRADIOL IN HET TUMORWEEFSEL VAN PATIENTEN MET PRIMAIR MAMMACARCINOOM 
J.M.M. Raemaekers1, L.V.A.M. Beex2, A.J.M. Koenders2, A.G.H. 
Smals2, G.F.F.M. Pieters2 , Th.J. Benraad2, P.W.C. Kloppenborg2 en 
de Werkgroep Mammae are i noom^ 
^Destijds m i l i t a i r a r ts , thans afdeling Endocrinologie, 2afdeling En-
docrinologie en Laboratorium voor Experimentele en Chemische Endocrinolo-
gie en 3 a f ( j e i i n g e n Heelkunde, Radiotherapie, Pathologische Anatomie en 
Röntgendiagnostiek van het St.Radboudziekenhuis, Nijmegen. 
SAMENVATTING 
Bi j 116 van 176 (66%) patiënten die in de periode 1974-1980 behan-
deld werden voor primair mammae arc i noom was onderzoek naar recep-
t o r a c t i v i t e i t voor estradol (RE) in het tunorweefsel pos i t ie f . Er 
werden geen s igni f icante verschi l len gevonden in l e e f t i j d , meno-
pauze-status en ui tbreiding van de tumor, t e r w i j l beide groepen 
i n i t i e e l op vergel i jkbare wijze werden behandeld. Van de 176 
patiënten overleden in de onderzoekperiode 23. Van de overige 153 
patiënten bedroeg de mediane observatieduur 34 maanden. Overeen-
komstig de meeste literatuurgegevens vonden wi j dat de kans op re-
c id ie f voor patiënten met een RE-negatieve tumor groter was dan 
voor patiënten met een RE-positieve tumor (P=0,05, en na u i t s l u i -
t ing van de patiënten die adjuvans-chemotherapie kregen, P<0,02). 
Dit verschil in kans op recid ief bestond overigens alleen b i j de 
patiënten b i j wie na de menopauze de diagnose primair mammacar-
cinoom was gesteld (P<0,02). De geschatte procentuele overlevings-
duur voor al le patiënten met een RE-negatieve tumor was korter dan 
die voor patiënten u i t de RE-positieve groep (P<0,01). 
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INLEIDING 
De kans dat het mammacarcinoom recidiveert hangt vooral af van de lokale 
en regionale ui tbreiding van de tumor b i j het stel len van de diagnose 
(Fisher e.a. 1969). Voor de prognose z i j n ook van belang de histologische 
en cytologische kenmerken van de tumor (Bloom en Field 1971; Black e.a. 
1975; Report of the primary Therapy of Breast Cancer Study Group 1978) en 
- wel l icht nog sterk onderschat - de anamnese van de patiente wat betreft 
de groeisnelheid van haar carcinoom (Charlson en Feinstein 1980). 
In de l i te ra tuur z i j n mededelingen gedaan over de prognostische beteke-
nis van receptorac t i v i te i t voor estradiol (RE) in het tumorweefsel van pa-
tiënten met een primair mammacarcinoom. In d i t onderzoek worden de resul-
taten beschreven van een onderzoek naar de kans op rec id ie f van het mamma-
carcinoom in re la t i e to t deze a c t i v i t e i t van de primaire tumor van patiën-
ten die in de periode 1974-1980 in het St.Radboudziekenhuis werden behan-
deld. Bovendien worden gegevens verstrekt over de geschatte overlevings-
duur van de patiënten u i t de groepen met of zonder receptorac t iv i te i t voor 
estradiol van de tumor. 
PATIENTEN EN ONDERZOEKMETHODEN 
Onderzocht werden de ziektegeschiedenissen van de 184 patiënten die in de 
periode 1974-1980 in het St.Radboudziekenhuis werden behandeld voor p r i -
mair mammacarcinoom en b i j wie onderzoek naar RE in het primaire tumor-
weefsel werd ve r r i ch t . Meting van de tumorgrootte geschiedde met behulp 
van mammografisch onderzoek. De stadiëring vond plaats op grond van de 
TNM-classif icatie (Union Internationale contre le cancer 1978). Tumoren 
met de aanduiding Т^ of J2 hebben een doorsnede van maximaal 2 respec­
t i e v e l i j k 5 cm, T3 betekent in deze c l a s s i f i c a t i e een tumorgrootte van 
meer dan 5 cm, t e r w i j l T4 f i x a t i e van de primaire tumor aan huid of 
borstwand impl iceert . Stadiëring van de okselkl ierstatus vond na de opera-
t i e door pathologisch-anatomisch onderzoek plaats. Daarbij betekent de 
aanduiding N+ dat voor tumor positieve lymfeklieren werden aangetoond en 
de aanduiding NQ dat d i t niet het geval was. Indien de okselkl ieren niet 
werden onderzocht, werd d i t met N7 aangegeven. (Patiënten b i j wie b i j 
het eerste onderzoek reeds metastasen op afstand waren gevonden, werden 
niet in d i t onderzoek opgenomen). Met de aldus gerubriceerde gegevens kon 
de volgende indeling worden gemaakt: 
1. patiënten met een "goede prognose", T^, T j , Ng, 
2. patiënten met een "onbekende prognose", T^, T j , N?, 
3. patiënten met een "slechte prognose", T3, T4; iedere Τ b i j N+. 
Primaire behandeling bestond u i t amputatio, gemodificeerd volgens Patey, 
of ablatio mammae of bleef beperkt tot excisie van de tumor. Deze ingrepen 
werden afhankeli jk van de loka l isa t ie en ui tbreid ing van de tumor en de 
oksellynfekl ierstatus al dan niet gevolgd door radiotherapie. Een klein 
aantal patiënten kreeg adjuvans chemotherapie met een combinatie van 
5 - f luo rourac i l , methotrexaat en cyclofosf amide. Patiënten die ten t i j d e 
van de i n i t i ë l e therapie langer dan 1 jaar geen menses hadden (n=94) of 
b i j wie eerder ovariectomie werd verr icht (n=2) of patiënten die na hys-
terectomie ouder dan 55 jaar waren (n=4), werden als postmenopauzaal ge-
c lass i f iceerd. Bi j patiënten die hysterectomie hadden ondergaan en jonger 
dan 55 jaar waren, werd de menopauzestatus als onbekend geclassificeerd 
(n=2). Onderzoek naar metastasen op afstand vond plaats vóór i n i t i ë l e be-
handeling en gedurende de eerste 2 jaren na primaire behandeling ten mins-
te om het ha l f jaar , daarna ten minste j a a r l i j k s . 
Onderzoek naar RE werd verr icht zoals door één onzer is beschreven 
(Koenders 1979). In het kort is de werkwijze als vo lg t : cytosol f ract ies 
van de tumor worden met б verschillende concentraties g e t r i t i e e r d estradi­
ol (Зн-Ез) geincubeerd. Om te kunnen corrigeren voor aspecifieke bin­
dingspl aatsen wordt steeds aan een deel van de cytosol f ract ies vóór incu-
batie n ie t - rad ioact ie f estradiol in overmaat toegevoegd. Na ins te l l ing van 
evenwicht tussen de hoeveelheid gebonden en niet-gebonden ЗН-Е2 wordt 
het v r i j e , gemerkte hormoon verwijderd door absorptie aan actieve kool. De 
verkregen gegevens worden geanalyseerd volgens Scatchard (1949). Alle t u ­
moren met aantoonbare specifieke bindingspl aatsen voor estradiol worden 
als RE-positief geclassif iceerd. De laagste gemeten specifieke bindingsac­
t i v i t e i t bedraagt 5 fmol/mg e i w i t . 
STATISTISCHE METHODEN 
Functies van geschatte overlevingsduur of recidiefkans werden berekend 
volgens de actuariële methode (Cutler en Ederer 1958; Gehan 1969) o f , voor 
kleinere groepen, volgens Kaplan en Meier (1958). Voor stat is t ische toet-
sing van verschi l len tussen dergel i jke functies werd gebruik gemaakt van 
een niet-parametrische toets (Gehan 1965; Mantel 1967) welke een modifica-
t i e is van de Wilcoxon-toets voor ongepaarde waarnemingen. De overige sta-
t i s t i sche bewerkingen werden uitgevoerd met behulp van de Mann-Whitney-
toets of de Chi-square-toets, met een onbetrouwbaarheidsdrempel van 0,05 
( tweezi jd ig) . 
RESULTATEN 
De gegevens van 8 van de 184 patiënten met primair mammae arc inoom b i j wie 
onderzoek werd verr icht naar de RE kwamen niet in aanmerking voor bewer-
king in d i t onderzoek wegens: onvoldoende gegevens over het ziekteverloop, 
onbetrouwbare uitkomst van het RE-onderzoek, endocriene maatregelen als 
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onderdeel van de primaire behandeling of de aanwezigheid van een tweede 
kwaadaardige tumor. Van de 176 overige patiënten overleden 23 in de onder-
zoekperiode aan rechtstreekse gevolgen van het manmacarcinoom. De mediane 
observatieduur van de 153 niet overleden patiënten bedroeg 34 maanden (u i -
terste waarden 3-83 maanden). Van de 176 patiënten met primair manmacarci-
noom hadden 116 (56«) een RE-positieve tumor. B i j 60 (34%) van de 
patiënten was de uitkomst van d i t onderzoek negatief. In Tabel 1 z i j n de 
kl inische gegevens van de patiënten u i t beide groepen samengevat en 
daaruit b l i j k t dat er geen s ta t is t isch s igni f icante verschi l len werden 
gevonden in gemiddelde l e e f t i j d , inenopauzestatus, u i tbreid ing van de 
primaire tumor en de toegepaste behandeling tussen de groepen patiënten 
met een RE-positieve of -negatieve tumor. 
In Figuur 1 is de kans op rec id ief van het mammae arc inoom weergegeven 
voor de dr ie groepen patiënten die op grond van de ui tbreid ing van de p r i -
maire tumor waren geclassif iceerd als patiënten met een goede, slechte of 
onbekende prognose. Zoals te verwachten, hadden patiënten met een lokaal 
of regionaal reeds uitgebreid mammacarcinoom een grotere kans op rec id ie f 
dan de groep patiënten met een goede prognose. De curve van de groep pa t i -
ënten van wie de prognose niet bekend was en d ie , naar men mag aannemen, 
is sanengesteld u i t patiënten met tunor posit ieve en negatieve okselk l ie-
ren, neemt een tussenpositie i n . Volgens de curven kan verwacht worden dat 
ongeveer 15% van de patiënten met een goede prognose en 30% van de patiën-
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FIG. 1. Kans op r e c i d i e f met betrekking t o t de lokale en regionale u i t ­
breiding van de primaire tumor (R, aantal patiënten met een rec id ie f ) . 
Uit Tabel 2 is te lezen dat van de 116 patiënten met een RE-positieve 
tumor er in de observatieperiode 25 een recid ief kregen, t e rw i j l d i t aan-
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TABEL 1. KLINISCHE GEGEVENS EN BEHANDELING VAN DE 176 PATIENTEN MET PRI-
MAIR MAMMACARCINOOM IN VERBAND MET DE RECEPTORACTIVITEIT VOOR 
ESTRADIOL VAN DE TUMOR. 
Lee f t i j d * 
gemiddelde l e e f t i j d 
t S (jaren) 


































anputatie (Patey) 60 (52%) 25 (41%) 
ablatie 40 (34%) 23 (39%) 
beperkte excisie 16 (14%) 12 (20%) 
Radiotherapie** 81 (71%) 46 (77%) 
Adjuvans-chemotherapie** 19 (16%) 5 ( 8%) 
* Bi j toetsing met de toets van Wilcoxon werd geen s ign i f i cant ie gevon-
den. 
** B i j toetsing met de Chi-square-toets werd geen s ign i f i can t ie gevonden. 
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ta l recidieven b i j de 60 patiënten met een RE-negatieve tumor 20 bedroeg. 
Procentueel was de frequentie van recidieven in de groep patiënten met een 
RE-negatieve tumor (n iet s igni f icant) groter dan in de groep met een RE-
positieve tumor, 33% t . o . v . 21% (P>0,1). De kans op rec id ie f van het mam-
macarcinoom, actuarieel berekend, is wel s ign i f icant verschil lend tussen 
beide groepen (Fig.2, P=0,05). Dit verschil in kans op rec id ie f tussen 
patiënten met een RE-positieve en RE-negatieve tumor bedroeg na 30 maanden 
10%. Dit verschil in kans op recid ief wordt du idel i jker indien de patiën-
ten die adjuv ans-chemother api e kregen buiten de analyse werden gehouden, 
n l . 20% (Fig.3, P<0,02). 
TABEL 2. GEGEVENS OVER HET AANTAL RECIDIEVEN IN VERBAND MET DE RECEPTOR-
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B i j indeling van de patiënten naar de menopauzestatus ten t i j d e van de 
primaire behandeling werden binnen de pre- of postmenopauzale groep, tus-
sen de patiënten met een RE-positieve of RE-negatieve tumor, geen s ta t i s -
t isch s igni f icante verschi l len gevonden in gemiddelde l e e f t i j d , lokale of 
regionale ui tbreiding van de tumor of i n i t i ë l e behandeling. Figuur 4 laat 
zien dat de kans op rec id ie f voor de postmenopauzale patiënten met een 
RE-positieve tumor s ign i f icant kleiner is dan voor de patiënten met een 
RE-negatieve tumor (P<0,02). Na 30 maanden bedroeg d i t verschil 20%. Het 
verschil in kans op rec id ie f tussen de patiënten met een RE-positieve of 
RE-negatieve tumor bleek vooral te worden veroorzaakt door de 5 patiënten 
met een lokaal of regionaal rec id ief van de timor (van wie 1 in de RE-po-
si t ieve groep en 4 in de RE-negatieve groep). Bi j de groep premenopauzale 
patiënten werd een dergel i jk verschil in kans op rec id ie f n iet waargenomen 
(Fig.5) . Bi j de berekening van deze functies werden de patiënten die adju-
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FIG. 2. Kans op r e c i d i e f met betrekking t o t de r e c e p t o r a c t i v i t e i t voor 
estradiol (RE) van de primaire tumor (R, aantal patiënten met een r e c i -
d i e f ) . 
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FIG. 3. Kans op r e c i d i e f met betrekking t o t de r e c e p t o r a c t i v i t e i t voor 
estradiol van de primaire timor. Uitgezonderd werden de patiënten die ad-
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FIG. 4. Kans op r e c i d i e f van postmenopauzaie patiënten met betrekking to t 
de receptorac t i v i te i t voor estradiol van de primaire tumor, uitgezonderd 
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FIG. 5. Kans op r e c i d i e f van prenienopauzale patiënten met betrekking to t 
de receptorac t i v i te i t voor estradiol van de primaire tumor, uitgezonderd 
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FIG. 6. Kans op r e c i d i e f van postmenopauzale patiënten ingedeeld naar lo -
kale en regionale u i tbreid ing van de tumor met betrekking tot de receptor-
a c t i v i t e i t voor estradiol van het primaire carcinoom, uitgezonderd de pa-
t iënten die adjuvans-chemotherapie kregen. 
Als we de groep postmenopauzale patiënten met een RE-positieve of RE-nega-
t ieve tumor verder onderverdelen op grond van de lokale en regionale u i t -
breiding van de tumor, werd steeds een overeenkomstig verloop gezien van 
de kans op rec id ie f zoals in de hele groep postmenopauzale patiënten met 
een RE-positieve of RE-negatieve tumor (F ig .6) . Wanneer deze onderverde-
l ing ook toegepast werd b i j de premenopauzale patiënten, dan werd in deze 
subgroepen geen s ign i f icant verschil gevonden in de kans op recid ief voor 
de patiënten met een RE-positieve of RE-negatieve tumor. 
Van de 116 patiënten met een RE-positieve tumor overleden er in de ob-
servatieperiode 11 (9,5%) en van de 60 patiënten met een RE-negatieve 
tumor 12 (20%,0,05<P<0,1). In Figuur 7 is de geschatte procentuele over-
levingsduur van a l le patiënten in re la t i e to t de RE van het tumorweefsel 
weergegeven. Ook deze actuarieel berekende curve verloopt s igni f icant gun-
st iger voor de groep patiënten met een RE-positieve tumor dan voor die met 
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FIG. 7. Geschatte overlevingsduur van de patiënten met primair mammacar-
cinoom, met betrekking tot de receptorac t i v i te i t voor estradiol in het 
tumorweefsel, uitgezonderd de patiënten die adjuvans-chemotherapie kregen 
(n=24;t =aantal overleden patiënten). 
BESCHOUWING 
Uit de resultaten van d i t onderzoek b l i j k t dat de postmenopauzale pat iën-
ten met een RE-negatief primair mammae arc inoom, binnen de gegeven observa-
tieperiode s ign i f icant meer kans hadden om metastasen te kr i jgen dan post-
menopauzale patiënten met een RE-positieve tumor. Dit verschil in kans op 
rec id ie f bedroeg na 30 maanden 20%. De groepen postmenopauzale patiënten 
met een RE-positieve of RE-negatieve tumor waren ten aanzien van andere 
prognostische kenmerken niet s iqn i f icant verschi l lend samengesteld. Indien 
de groep postmenopauzale patiënten werd onderverdeeld naar lokale en 
regionale ui tbreiding van de t imor, was ook binnen deze subgroepen de 
prognose voor patiënten met een RE-negatieve tumor slechter dan voor pa-
t iënten met een RE-positieve tumor. Overigens was d i t verschil binnen de 
groep patiënten met een goede of onbekende prognose j u i s t n iet s ign i f icant 
(P=0,08). 
B i j premenopauzale patiënten met een RE-positieve of een RE-negatieve 
tumor was het verloop van de geschatte kans op rec id ie f ongeveer g e l i j k . 
Dit gold ook voor subgroepen van premenopauzale patiënten ingedeeld naar 
de lokale en regionale u i tbreid ing van de tumor. In de l i te ra tuur wordt 
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door de meeste auteurs aangegeven dat patiënten met RE-negatief primair 
mammacarcinoom een slechtere prognose hebben dan patiënten met een RE-po-
s i t ieve tumor (Knight е.a. 1977; Maynard е.a. 1978; Rich е.a. 1978; 
Allegra е.a. 1979; Hähnel е.a. 1979; Cooke е.a. 1980; Gapinsky en Donegan 
1980). De daarbij gevonden verschi l len in kans op rec id ief variëren van 12 
tot 30%. Enkele auteurs vinden geen s igni f icant verschil in kans op r e c i -
d ie f tussen patiënten met een RE-positieve en een RE-negatieve tumor 
(Cheix e.a. 1980; H i l f е.a. 1980). 
Opvallend in het onderzoek van Cooke e.a. (1980) en van Allegra e.a. 
(1979) i s , dat het verschi l in kans op r e c i d i e f ten gunste van patiënten 
met een RE-positieve tumor het du ide l i j ks t is b i j j u i s t premenopauzale pa-
t iënten. Daarentegen vonden Rainer e.a. (1980) dat het verschil in kans op 
rec id ie f tussen patiënten met een RE-positieve en een RE-negatieve tumor 
het grootst was in de postmenopauzale groepen, t e rw i j l b i j premenopauzale 
patiënten geen s ign i f icant verschil in kans op rec id ie f werd aangetoond. 
Overigens werden in deze publ ikat ies de begrippen pre- of postmenopauzaal 
niet gedefinieerd. B i j de andere genoemde onderzoekingen werd de menopau-
zestatus niet in het onderzoek betrokken. 
Vrijwel a l le genoemde auteurs leggen er de nadruk op dat de door hen 
gevonden prognostische betekenis van de RE-act iv i te i t onafhankelijk is van 
de uitgebreidheid van de primaire tumor. Dus, binnen subgroepen ingedeeld 
naar de lymfekl ierstatus van de oksel, werd ook een s ign i f icant verschi l 
in kans op rec id ie f tussen patiënten met een RE-positieve of RE-negatieve 
tumor gevonden (Knight e.a. 1977; Maynard e.a. 1978; Allegra e.a. 1979; 
Hähnel e.a. 1979; Cooke e.a. 1980). Ook de gegevens van de postmenopauzale 
patiënten u i t d i t onderzoek wijzen erop dat de prognostische waarde van 
het RE-onderzoek onafhankelijk is van de lokale en regionale tumoruitbrei-
ding. Bi j de bestudering van de l i te ra tuur die handelt over de prognosti-
sche betekenis van de receptorac t iv i te i t voor estradiol va l t op, dat het 
percentage patiënten met een RE-negatieve tumor meestal hoog i s , 43-57%. 
Alleen Knight e.a. (1977) en Cheix e.a. (1980) vonden lagere percentages, 
37, respect ievel i jk 22. In ons onderzoek bedroeg d i t percentage 34. Dit 
komt goed overeen met het percentage RE-neqatieve tumoren van ongeveer 33 
dat in de l i t e ra tuu r voor grote groepen patiënten met primair mammacarci-
noom wordt vermeld (McGuire e.a. 1975; Saez e.a. 1976; Barnes 1977; 
Lippman en Allegra 1978; Koenders 1979). 
In de onderzoekingen betreffende de prognose van mammacarcinoom zouden 
de soms aanzienl i jk van deze norm afwijkende percentages voor RE-negatieve 
tumoren kunnen wijzen op een belangrijke select ie van patiënten. Well icht 
is d i t een van de factoren waardoor er zulke opvallende verschi l len z i j n 
in de resultaten van het onderzoek naar de prognostische betekenis van 
RE-act iv i te i t in tumc.-weefsel van pre- of postmenopauzale patiënten met 
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primair mammacarcinoom. Overigens kunnen h ie rb i j ook verschi l len in metho-
den van RE-onderzoek, dan wel verschi l len in mediane observatieduur of 
verschi l len in d e f i n i t i e van de menopauzestatus van belang z i j n . 
In ons onderzoek b l i j k t dat binnen de genoemde observatieperiode de 
overlevingskans voor de patiënten met een RE-positieve tumor s igni f icant 
gunstiger was dan die voor patiënten met een RE-negatieve tumor. Het aan-
ta l reeds overleden patiënten was te gering om betrouwbare uitspraken te 
doen over de overlevingskansen binnen subgroepen van patiënten ingedeeld 
naar menopauzestatus of primaire tumoruitbreiding. Hähne! е.a. (1979) v in­
den eveneens een gunstiger levensverwachting voor patiënten met een RE-po-
s i t ieve tumor dan voor patiënten met een RE-negatieve tumor. Bishop e.a. 
(1979) stelden d i t eveneens b i j de door hen onderzochte groep postmenopau-
zale patiënten met primair mammacarcinoom vast. 
Overigens dient b i j verschi l len in geschatte overlevingsduur rekening te 
worden gehouden met de verschillende resultaten van vooral endocriene 
maatregelen b i j patiënten met gemetastaseerd mammacarcinoom met een RE-po-
s i t ieve of een RE-negatieve tumor (Beex 1979). Uit gegevens van Rossi 
e.a. (1980) en Fisher e.a. (1975) b l i j k t dat adjuvans-chemotherapie b i j 
postmenopauzale patiënten met primair mammacarcinoom van weinig betekenis 
i s . Uit gegevens van ons eigen onderzoek en de daarop betrekking hebbende 
l i te ra tuur b l i j k t ook dat het ziektebeloop voor postmenopauzale patiënten 
met een RE-positief primair mammacarcinoom aanmerkelijk gunstiger is dan 
voor patiënten met een RE-negatieve tunor. Deze beide bevindingen recht-
vaardigen grote terughoudendheid b i j het voorschrijven van adjuvans-chemo-
therapie aan postmenopauzale patiënten met een RE-positief primair mamma-
carcinoom. 
SUMMARY 
THE PROGNOSTIC SIGNIFICANCE OF RECEPTOR ACTIVITY FOR OESTRADIOL IN TUMOUR 
TISSUE OF PATIENTS WITH PRIMARY BREAST CANCER. 
Specific receptor activity for oestradiol (ER) was found in 116 of 176 
(66%) tunours of patients treated for primary breast cancer between 1974 
and 1981; 60 patients had ER negative tumours. Groups of patients with ER 
positive or ER negative tumours did not differ significantly in clinical 
characteristics. According to most data in the literature, the estimated 
relapse free period was significantly longer for patients whose tumours 
contained ER activity as compared to patients with ER negative breast 
cancer (P=0.05, and if patients receiving adjuvant chemotherapy were 
excluded P<0.02). However, this difference in risk of recurrence existed 
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only in the postmenopausal group of patients (P<0.02). Survival functions 
for patients with ER positive tumours were significantly better, compared 
to those for patients with ER negative tumours (P<0.01). 
LITERATUUR 
Allegra, J . , M. Lippman, R. Simon e.a. (1979) Cancer Treat. Rep. 63, 1271. 
Barnes, D. (1977) Europ. J. Cancer 13, 1133. 
Beex, L. (1979) Klinische betekenis van de recep to rac t i v i te i t voor oestra-
d io l in tumorweefsel van patiënten met een gemetastaseerd mammacar-
cinoom. Proefschri f t Nijmegen. 
Bishop, H., С El shan, R. BI aney e.a. (1979) Lancet I I , 283. 
Black, M., T. Barclay en B. Han Key (1975) Cancer (Philad.) 36, 2048. 
Bloom, H. en J. Field (1971) Cancer (Philad.) 28, 1580. 
Charlson, M. en A. Feinstein (1980) Amer. J. Med. 69, 527. 
Cheix, F., A. Biron, С B a i l l y e.a. (1980) Nouv.Presse méd. 9, 933. 
Cooke, T., D. George, R. Shields e.a. (1980) Europ. J. Cancer, Suppl. I , 
53. 
Cutler, S. en F. Ederer (1958) J.chron. Dis. 8, 699. 
Fisher, В., P. Carbone en S. Economo (1975) New Engl. J. Med. 292, 117. 
Fisher, В., N. Slack, J. Bross e.a. (1969) Cancer (Philad.) 24, 1071. 
Gapinsky, P. en W. Donegan (1980) Surgery 88, 386. 
Gehan, E. (1965) Biometrika 52, 203; (1969) J . chron. Dis. 21, 629. 
Hähnel, R., T. Woodings en A. Vivian (1979) Cancer (Philad.) 44, 671. 
H i l f , R., M. Feldstein, S. Gibson e.a. (1980) Cancer (Philad.) 45, 1993. 
Kaplan, E. en P. Meier (1958) J. /Vner. s ta t . Ass. 53, 457. 
Knight, W., R. Livingston, E. Gregory e.a. (1977) Cancer Res. 37, 4669. 
Koenders, Α. (1979) Estradiol and progesterone receptors in experimental 
and human breast tumours. Proefschrift Nijmegen. 
Lippman, M. en J. Al legra (1978) New Engl. J. Med. 17, 930. 
Mantel, Ν. (1967) Biometrics 23, 65. 
Maynard, P., R. Blarney, С. Eiston e.a. (1978) Cancer Res. 38, 4292. 
McGuire, W., 0. Pearson en Α. Segaloff (1975) In: W.L. McGuire, P.D. 
Carbone en Ε.P. Volmer, Estrogen receptors in human breast cancer, 
Ы. 17. Raven, New York. 
Rainer, H., P. Bettelheim, Ch. Bieglmayer e.a. (1980) Wien, kl i n . Wschr. 
92, 796. 
Report of the primary therapy of breast cancer study group (1980) Cancer 
(Philad.) 42, 2809. 
Rich, M., P. Furmanski, S. Brooks e.a. (1978) Cancer Res. 38, 4296. 
Rossi, Α., G. Bonadonna, G. Tancini e.a. (1980) Europ. J. Cancer (Suppl. 
I ) , 149. 
Saez, S., C. Chouvet, F. Sakai e.a. (1976) In: Hormones et cancer du 
sein. Les édit ions de l ' I n s t i t u t national de la santé et de la re-
cherche médicale (Inserm), vo l . 55, Ы.45. Ministère de la Santé, 
Par i j s . 
Scatchard, G. (1949) Ann. N.Y. Acad. Sci. 51, 660. 
Union Internationale contre le cancer (1978) TNM c lass i f i ca t ion of malig-
nant t m o r s . 3e druk, UICC, Genève. 
64 
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SUMMARY 
Specific estrogen receptor ac t i v i t y (ER) was found in 115 of 175 
(66%) tumors of patients treated for primary breast cancer in the 
period 1974-1981; 60 patients had ER-negative tumors. Al l patients 
were under observation for at least 48 months (median 76 months). 
The 24 patients who received adjuvant chemotherapy as part of 
the i r i n i t i a l treatment, were excluded from the analysis of the 
disease-free interval (DFI). Groups of patients with ER-positive 
or ER-negative tumors did not d i f f e r s ign i f i can t l y in c l i n i ca l 
character is t ics. Patients with ER-positive tumors had a s i g n i f i -
cantly longer DFI than those with ER-negative tumors only in the 
f i r s t year after i n i t i a l treatment. After prolonged observation a 
s ign i f icant di f ference in recurrence rates was no longer found. In 
premenopausal women, the DFI was not d i f fe ren t for those with ER-
posi t ive compared to those with ER-negative tumors, not even in 
the f i r s t year of observation. However, in postmenopausal women, 
those with ER-positive tumors had a s ign i f i can t l y longer DFI up to 
3 years after i n i t i a l treatment but not thereaf ter . There was no 
difference in DFI between the ER-positive and ER-negative groups 
when the tumor stage was taken into account. I t is concluded that 
the ER status of the primary timor affects prognosis only on the 
short term. 
Breast Canoer Res Treat 6,123-130,1985 
INTRODUCTION 
The prognostic signif icance of measurement of estrogen receptor (ER) con­
tent in tumor tissue of patients with primary breast cancer with regard to 
recurrence rate is s t i l l under debate at t h i s t ime. Most studies, with a 
short follow-up period, indicate a more favourable prognosis for patients 
with ER-positive tumors (1-27). However, in most of these studies the es­
timated disease-free intervals (DFI) were calculated on r e l a t i v e l y few re­
currences, which makes s t a t i s t i c a l analyses less r e l i a b l e . Studies with 
more prolonged follow-up suggest that the favourable effect of ER p o s i t i -
v i t y on recurrence rate diminishes gradually in time (28-32). Here we pre­
sent our data on recurrence rates in a group of 175 patients with primary 
breast cancer related to the ER status of the primary tumor and the tumor 
stage, a l l under protocol follow-up for at least 48 months. 
PATIENTS AND METHODS 
In the period 1974-1981, ER a c t i v i t y was assessed in the tumor tissue of 
175 patients with primary breast cancer who underwent surgery in t h i s cen­
t e r . In none of these patients was there evidence of d istant metastases. 
The surgery consisted of modified radical mastectomy, simple mastectomy, 
or excisional biopsy. Most patients received postsurgical radiotherapy 
(71%). Only 24 patients received adjuvant chemotherapy consisting of the 
combination of 5 - f l u o r o u r a c i l , methotrexate, and cyclophosphamide. Al l 
patients were followed at regular i n t e r v a l s , at the mim'miri twice yearly 
in the f i r s t two years and at least yearly thereaf ter . Evidence of recur­
rent disease was confirmed by biopsy, whenever possible. For the purpose 
of t h i s study the follow-up of the patients ended July 1st, 1984. None of 
the patients was lost to follow-up. The 9 patients (ER+, n=4; ER-, n=5) 
who died in the disease-free interval of causes unrelated to breast can­
cer, are included as "disease-free" in the analysis. The DFI was defined 
as the period between date of surgery and date of f i r s t relapse. The dia­
meter of the primary tumor was measured by mammography or by pathologic 
examination and c lass i f ied according to the U.I.C.C. (1978) (33). On the 
basis of diameter of the primary tumor and lymph node invasion (NQ = no 
invasion, Ν+ = invasion, and N? = invasion unknown), the patients were 
c lass i f ied into three subgroups: 
i ) patients with good prognosis: T^TJNQ (n=49) 
i i ) patients with poor prognosis: T3T4 irrespect ive of N status or 
N+ irrespective of Τ status (n=89) 
i i i ) patients with unknown prognosis: T1T2N? (n=37). 
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The menopausal state was defined as postmenopausal when menses had ceased 
at least 12 months (n=93) or after previous ovariectomy (n=2) or when pa-
t ients were older than 55 years and had a hysterectomy in the past (n=4). 
The two patients who were younger than 55 years and underwent hysterectomy 
were to be c lass i f ied as menopausal state "unknown". Thus, the remaining 
74 patients were premenopausal. The ER assays were performed using the 
dextran-coated charcoal method as described ear l ier (34). ER levels > 5 
fmol/mg protein are considered ER posi t ive. 
STATISTICAL METHODS 
Analysis of the expected disease-free interval was carried out by the 
Kaplan-Meier method (35). S ta t is t ica l comparisons between the relapse 
functions were made using the Gehan-Mantel non-parametric test (P denoted 
by p) (36,37). Further s ta t i s t i ca l analysis was performed using Fisher's 
Chi Square test (P denoted by p*) and Wilcoxon's two sample test (P denot-
ed by p**). 
RESULTS 
CLINICAL CHARACTERISTICS AND ER STATUS (Table 1) 
Cl inical character is t ics of the 175 patients studied are shown in Table 
1. One hundred and f i f teen of these patients (66%) had an ER-positive 
tumor. There were no s ign i f icant differences in any of the c l i n i ca l cha-
rac ter is t i cs between the groups of patients with ER posi t ive and ER nega-
t ive tumors. The v a l i d i t y of our c lass i f i ca t ion based on tumor extension 
and lymph node staging is c lear ly i l l us t ra ted by the differences in ex-
pected DFI between the groups with good and poor prognosis ( F i g . l ) . 
DISEASE-FREE INTERVAL (Table 2) 
Analysis of the DFI is res t r ic ted to those patients who did not receive 
adjuvant chemotherapy as part of the i r i n i t i a l treatment (n=151). Al l 
these were observed for at least 48 months with a longest follow-up period 
of 130 months. No relapse was observed in 84 of the 151 patients (55.6%) 
after a median follow-up time of 76 months. Of the 67 patients who relaps-
ed (44.4%), the shortest interval to recurrence was 2 months and the long-
est 99 months (Table 2) . 
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TABLE 1. CLINICAL CHARACTERISTICS OF THE 175 PATIENTS WITH PRIMARY BREAST 
CANCER AND THE ER STATUS OF THE TUMOR TISSUE. 
ER-positive 
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FIG. 1. Estimated disease-free interval and staging according to tumor 
extension and lymph node invasion (n=number of pat ients; r=mmber of 
recurrences). 
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TABLE 2. RECURRENCE AND ER STATUS OF THE PRIMARY TUMOR (ADJUVANT CHEMO-
THERAPY EXCLUDED). 
Recurrence (n) 
Time to recurrence (months) 
med i an 








32 ± 25 





37 ± 26* 





20 ± 18* 
3 - 74 
DFI, ER STATUS AND MENOPAUSAL STATE (Table 2, Figs. 2 and 3) 
Table 2 shows that in the group of patients with ER-positive tumors 
(n=96), recurr ing disease developed in 44 patients (46%) whereas in the 
ER-negative tumor group (n=55), metastases developed in 23 patients (42%) 
(p*>0.1). However, the mean duration to recurrence was s ign i f i can t l y long-
er for the patients with ER-positive tumors than for those with ER nega-
t i ve tumors: 37 vs. 20 months (p**<0.01). 
Analysing the DFI 1 year after i n i t i a l treatment of each pat ient , there 
was a s ign i f icant difference in DFI in favour of the group of patients 
with ER-positive tumors (p<0.05). After 24 and 36 months the differences 
in DFI between the two groups were merely indicat ive (0.05<p<0.1). How-
ever, analysing the data after 48 months, a s ign i f icant difference in DFI 
between the two groups was no longer found (p>0.1). Accordingly, as shown 
in Fig.2 after a median follow-up of 76 months, no s ign i f icant difference 
was present between the two groups (p>0.1). 
With regard to the menopausal state, in the premenopausal women no sta-
t i s t i c a l l y s ign i f icant difference in recurrence rate was found between the 
ER-positive and ER-negative group at any time of observation, not even in 
the f i r s t year (data not shown). The recurrence rate in the ER-positive 
group of postmenopausal women was s ign i f i can t l y lower after 12 (p<0.02), 
24 (p=0.05), and s t i l l after 36 months (p<0.05). At longer follow-up th is 
difference in recurrence rate had disappeared: af ter 5 years of observa-
t ion 63% of the postmenopausal group of patients with ER-positive tunors 
and 61% of the ER-negative group were expected to be disease-free (p>0.1) 
(F ig .3) . The patterns of Figures 2 and 3 suggest that when patients with 
ER-negative primary breast cancer develop metastases, they tend to do so 
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FIG. 2. Estimated disease-free interval and ER status of the primary 
tumor. 
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FIG. 3. Estimated disease-free interval and ER status of the primary 
tumor in postmenopausal pat ients. 
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number of recurrences in the ER-negative group decreases: only 4 of 35 pa­
t ients with ER-negative tumors who were disease-free for more than 3 years 
relapsed thereafter, whereas in the ER-positive group 22 of 73 developed 
metastases (0.05<p*<0.1). 
DPI AND PROGNOSTIC STAGING BASED ON TIMOR EXTENSION AND LYMPH NODE STATUS 
(Table 1, F i g . l ) 
As expected, the patients with good prognosis had a s i g n i f i c a n t l y longer 
DFI than the patients with poor prognosis as shown in F i g . l . At any dura­
t i o n of follow-up patients with poor prognosis had indeed a s i g n i f i c a n t l y 
higher recurrence rate than the patients with good prognosis. The patients 
with unknown prognosis had an intermediate r i s k of relapse at any time of 
fol low-up, as was expected since th is group of patients (n=36) is composed 
of patients with and without a x i l l a r y lymph node involvement. In none of 
the three defined subgroups was a difference in DFI found between the 
groups of patients with ER-positive and ER-negative tumors (data not 
shown). 
DFI AND QUANTITATIVE ER ACTIVITY 






















(n=34) (n = 27) 
Postmenopausal 
FIG. 4. Absolute ER values of the ER-positive tumors of those patients 
who relapsed and those who renained disease-free, related to menopausal 
state (n=number of pat ients) . 
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There were no s ign i f icant differences in absolute ER levels between the 
patients with ER-positive tumors who relapsed and those who did not. As 
depicted in Fig.4, t h i s holds true in the premenopausal as well as in the 
postmenopausal pat ients. The median ER level in the premenopausal group of 
patients who did not relapse was 47 fmol/mg protein and for those who re­
lapsed 42 fmol/mg prote in. In the postmenopausal group of pat ients, the 
median values were 145 and 120 fmol/mg protein respectively. 
DISCUSSION 
E a r l i e r , we reported that patients with ER-positive primary breast cancer 
have a s i g n i f i c a n t l y longer estimated disease-free interval than patients 
with ER-negative tumors, although the difference was only s igni f icant in 
the postmenopausal group of patients (22). Those results were based on ac­
t u a r i a l analysis of recurrence after a median follow-up of 34 months. The 
present study analysed the recurrence rate of primary breast cancer r e l a t ­
ed to the ER status of the tunor on the strength of the recurrences in a 
rather large number of patients who were a l l under observation for at 
least 4 years, with the median follow-up of the whole group being 76 
months. Our analysis shows that the prognosis in primary breast cancer in 
the short term is affected indeed by the ER status. However, f o r the pa­
t ients with ER-positive tumors there seems to be a gradual but sustained 
r i s k of relapse throughout f u l l length of fol low-up, whereas patients with 
ER-negative tumors seem to develop metastases mainly in the f i r s t 3 years 
after i n i t i a l treatment. This is substantiated by our f inding that the 
mean disease-free interval of the patients who relapsed was s i g n i f i c a n t l y 
longer for the ER-positive than for the ER-negative group. 
In the l i t e r a t u r e , most authors have reported a s i g n i f i c a n t l y longer 
estimated disease-free interval for the patients with ER-positive tumors, 
based on estimations of recurrence rates after a r e l a t i v e l y short fo l low-
up (Table ЗА) (1-27). Knight et a l . ( l ) , Maynard et a l . ( 3 ) , Blarney et 
31.(12), Kinne et a l . ( 1 9 ) , and Clark et al.(27) found s igni f icant d i f f e r ­
ences only in the group of patients with lymph node invasion, whereas 
Valagussa et a l . (16) and Crowe et a l . (21) established s igni f icant d i f f e r ­
ences only in the lymph-node negative groups. Samaan et a l . ( 1 8 ) , Valagussa 
et a l . ( 1 6 ) , and Logan (25) found s ign i f icant differences only in the pre­
menopausal pat ients, whereas Pichón et a l . ( 8 ) , Rainer et a l . (13 ) , and 
Raemaekers et al.(22) stated that there was only a s igni f icant dif ference 
in the postmenopausal pat ients. A second group of authors (Table 3B) (38-
50) found no difference at a l l between the ER-positive and ER-negative 
groups of pat ients, ei ther after re la t i ve l y short follow-up (Bloom et a l . 
(39), Skinner et a l . (40) , Kaufman et a l . (41) , Stewart et al.(42 and 43), 
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TABLE 3. REVIEW OF LITERATURE ON DISEASE-FREE INTERVAL AND ER STATUS OF 
THE TUMOR IN PATIENTS WITH PRIMARY BREAST CANCER. 
Author Number of ER+ Follow-up Comments 
patients % months 
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Ciatto et a l . ( 44 ) , Mason et a l . (45 ) , Howell et a l . (47)) or after more pro-
longed follow-up (H i l f et a l . (47) , Caldarola et a l . (46) , Alanko et 
a l . (48 ) , Aamdal et al .(49) and Pari et a l . ( 50 ) ) . Our data are in accord-
ance with those of Hähnel et a l . (28) , Furmanski et a l . (29 ) , v. Mai l lot et 
a l . (30 ) , Howat et a l . (31 ) , and Saez et al .(32) (Table 3C). These authors 
found s igni f icant differences in relapse rates only in the short term. 
Our data indicate that patients with ER-positive breast cancer on long-
term follow-up have no lower r isk of recurring disease than those with 
ER-negative tumors, unlike the results of analysis on short-term follow-up 
which are indicat ive of fewer recurrences in the ER-positive group, at 
least in postmenopausal women. 
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ABSTRACT 
The prognostic signif icance of progesterone receptor a c t i v i t y 
(PgR) with regard to the estimated relapse-free survival (RFS) was 
studied in 350 one-center patients with primary breast cancer. Al l 
receptor assays were performed in one laboratory; PgR levels > 10 
fmol/mg protein were considered pos i t ive. Univariate as well as 
mult ivar iate s t a t i s t i ca l analyses were used to examine the prog-
nostic signif icance of several variables. Eighty-nine of the 350 
patients received adjuvant chemotherapy with the combination of 
cyclophosphamide, methotrexate and 5- f luorouraci l (CMF). The 
median observation period was 69 months (range 12-125 months). In 
the group of 261 patients who did not receive adjuvant CMF, the 
PgR-status lacked prognostic signi f icance. Only the lymph node 
status s ign i f i can ly affected the RFS (p<0.00001). In contrast, in 
the CMF-treated group of pat ients, the PgR-status was the most 
powerful predictor of recurrence (p<0.0001). The menopausal and 
the lymph-node state increased the predict ive value of PgR 
(p<0.001). Premenopausal CMF-treated patients with PgR +ve tumors 
had a s ign i f i can t l y longer RFS than those with PgR -ve tunors 
(p<0.02). The present data urge the need of a reappraisal of the 
prognostic signif icance of PgR and of the mechanism of action of 
adjuvant chemotherapy in primary breast cancer. 
Breast Cancer Res Treat, 
Accepted for publication 
INTRODUCTION 
Several recent reports (1,2) suggest that progesterone receptor a c t i v i t y 
(PgR) measured in the tumor tissue of patients with primary breast cancer, 
might provide prognostic information with regard to the relapse-free sur­
vival (RFS). Other authors could not confirm these results (3,4). In the 
major i ty of the studies varying numbers of patients received systemic ad­
juvant therapies. From the data, i t i s not clear whether adjuvant t r e a t ­
ment regimens per se might have biased the outcome of these studies. 
In t h i s study, we report our experience on the prognostic signif icance 
of PgR in a non-selected group of one-center patients not treated with 
systemic adjuvant therapies. "Rie resul ts are compared to those obtained in 
a group of patients receiving adjuvant chemotherapy in the same period at 
our breast c l i n i c . 
PATIENTS AND METHODS 
In the period 1976 t i l l July 1985 PgR ( in addit ion to the estradiol recep­
tor a c t i v i t y , ER) was measured in the tumor t issue of 350 patients with 
primary breast cancer, a l l detected and treated in t h i s center. 
Twenty-one additional patients have been excluded from t h i s study because 
o f : i ) hormonal adjuvant therapy (n=18, postmenopausal ER+), i i ) i n s u f f i ­
cient follow-up data (n=2) or i i i ) mul t ip le metastases from 3 primaries 
( n = l ) . 
The surgical treatment consisted of a mastectomy or breast conserving 
lunpectomy. Seventy-two percent of the patients received post-surgical 
radiotherapy according to the TNM c l a s s i f i c a t i o n and/or local isat ion of 
the primary tumor. On the basis of the diameter of the primary tumor, 
assessed by mammographie or h istologic measurements (T c l a s s i f i c a t i o n , 
UICC, 1978) and the lymph-node invasion (Ng=no invasion, N+=invasion, 
N?=invasion unknown), the 350 patients were c l a s s i f i e d into 3 prognostic 
subgroups as described ear l ier (5): 
i ) patients with "good prognosis": T ^ N g 
i i ) patients with "poor prognosis": Т^Тц i rrespect ive of N 
or N+ irrespect ive of Τ 
i i i ) patients with "unknown prognosis": TjT^N? 
Table 1 shows the frequencies of the d i f f e r e n t subgroups of pat ients. Pa­
t i e n t s with good or unknown prognosis received no adjuvant chemotherapy. 
In the "poor prognosis" group, 125 patients did not receive adjuvant che­
motherapy. Reasons for not receiving chemotherapy were: i) assignment t o 
the control group in a randomised t r i a l on the ef fects of low dose adju­
vant chemotherapy, i i ) age > 70 years, i i i ) refusal of adjuvant chemothe­
rapy, iv) protocol v i o l a t i o n . The remaining 89 pat ients, a l l < 70 years of 
age, received adjuvant chemotherapy (the combination of cyclophosphamide, 
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methotrexate, 5-fluorouracil. · CMF). Before 1981 patients received low 
doses of CMF (13-24 cycles, η = 22). After 1981 a l l patients with poor 
prognosis < 70 yrs of age were e l i g i b l e for conventional doses of CIF (9 
cycles, η = 67). Postmenopausal patients with ER +ve tumors detected af ter 
1981, received a combination of chemotherapy and endocrine therapy and 
these patients were excluded from the present analysis because of the 
endocrine component in the adjuvant regimen. 
TABLE 1. STUDY GROUP. 
N = 350 
261 
N = 116 good prognosis 
N = 125 poor prognosis 
N = 20 unknown prognosis 
89 
N = 82 complete course 
N = 7 discontinuation 
The menopausal state was defined as described e a r l i e r (5). All patients 
were followed at the breast c l i n i c according to standard protocols. Evi­
dence of recurring disease was confirmed by biopsy whenever possible. A l l 
patients were under observation for at least one year, the observation 
period for the purpose of t h i s study ending July 1st, 1986. 
The RFS was defined as the period between the date of the primary local 
treatment and the date of f i r s t relapse. The 21 patients who died in the 
relapse-free interval of causes unrelated to breast cancer, were included 
as relapse-free u n t i l the date of the i r death. 
The PgR (and ER) assays were a l l performed in one laboratory using the 
dextran-coated charcoal method with mult iple-point Scatchard-plot analysis 
as described ear l ier ( 6 ) . Levels > 10 fmol/mg protein were considered 
receptor p o s i t i v e . 
Analysis of the expected RFS was carried out by the Kaplan-Meier method, 
whereas s t a t i s t i c a l comparisons between curves were made using Gehan's 
non-parametric (7) and the log rank test (8) (P denoted by ρ and p* res­
pect ively). The Cox's p a r t i a l l y non-parametric regression model was used 
to analyze the predict ive value of various combinations and interactions 
of prognostic variables in a mul t ivar iate manner (9). The putative prog­
nostic factors, included in the model, were the age, the menopausal state, 
NO ADJUVANT CMF N 
ADJUVANT CMF N 
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TABLE 2. CLINICAL CHARACTERISTICS OF THE PATIENTS NOT TREATED WITH ADJU­
VANT CMF RELATED TO THE PgR-STATUS OF THE TUMOR. 
Age (yr) 
Menopausal state 
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TABLE 3. CLINICAL CHARACTERISTICS OF THE CMF-TREATED PATIENTS RELATED TO 
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the size of the primary tumor, the number of involved lymph nodes, the 
surgical and radiotherapeutic treatment, the adjuvant chenotherapeutic 
regimen and the qua l i ta t ive and quant i tat ive ER- and PgR-status of the 
tumor. The data were processed with the Biomedical Computer Program Series 
(10). Further s ta t i s t i ca l analyses were performed using Fisher's Chi 




1. No adjuvant CMF 
Table 2 shows the c l i n i ca l character ist ics related to the PgR-status of 
the tumor in the 261 patients who did not receive adjuvant chemotherapy. 
Sixty percent of the patients had a PgR +ve tumor. There were no s i g n i f i -
cant differences in the c l i n i ca l character ist ics between the groups of 
patients with PgR +ve and PgR -ve tumors, except for the expectedly higher 
percentage of ER +ve tumors in the former (p**<0.0001). During the obser-
vation period with a median duration of 69 months, 26% of the patients 
with PgR +ve tumors and 28% of those with PgR -ve tumors had relapses. 
Fig. 1 shows that there was no s ign i f icant di f ference in the estimated RFS 
between the groups of patients with PgR +ve and PgR -ve tumors (p>0.1; 
p*>0.1): about 70% of the patients in both groups are expected to be re-
lapse-free af ter 5 years of observation. By taking the tumor stage into 
account, we found again no s igni f icant differences in the estimated RFS 
between the PgR +ve and PgR -ve groups of patients neither in the "good 
prognosis"-group nor in the "poor prognosis"-group (also shown in Fig. 1) 
(p>0.1; p*>0.1). I t has to be noted that within those two subgroups of 
patients the c l i n i ca l character ist ics did not d i f f e r s ign i f i can t l y between 
the PgR +ve and PgR -ve patients (data not shown). 
2. Adjuvant CMF 
Seven out of the 89 patients who received adjuvant CMF did not complete 
the planned course of the adjuvant treatment and, therefore, were excluded 
from the analysis. Table 3 shows the c l i n i ca l character is t ics of the re-
maining 82 patients related to the PgR-status of the tumor. Sixty-eight 
percent of the patients had a PgR +ve tumor. The two groups of patients 
did not d i f f e r s ign i f i can t l y in the mean age, the prognosis var iable, 
the CMF schedules nor in the length of the observation period. I t is of 
note that due to the adjuvant therapy protocol by which postmenopausal ER 
+ve patients (mostly PgR +ve) were assigned to hormonal treatment, the 
nunber of postmenopausal patients was s ign i f i can t l y lower in the PgR +ve 
group than in the PgR -ve one. Unlike our f indings in the non-adjuvant 
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relapse free 
"good prognosis" NO ADJUVANT 
V PgR. П.6Э r , 5 
PgB- n . 5 3 r . 
p > 0 1 
"poor prognosis" NO ADJUVANT 
p > 0 1 
PgH. П.8Э r . 3 1 
PgR- n . 4 2 r . 1 9 
60 Θ4 108 132 
time ( months ) 
FIG. 1. Estimated RFS and the PgR-status of the t imor. No adjuvant CMF. 
All patients (upper panel), patients with "good prognosis" (mid panel) and 
patients with "poor prognosis" (lower panel), (n=number of pat ients, 
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FIG. 2. Estimated RFS and the PgR-status of the tumor in the group of 
patients treated with adjuvant CMF. 
treated pat ients, PgR +ve patients had a lower relapse rate than the PgR 
-ve ones: 23% versus 65% respectively. 
F ig. 2 c lear ly shows that the PgR +ve patients treated with adjuvant 
CMF, had a s i g n i f i c a n t l y longer RFS than the PgR -ve pat ients: after 5 
years of observation about 70% of the former and only 25% of the l a t t e r 
are expected to be relapse-free (p<0.0001; p*<0.0001). The prognostic s ig­
nif icance of PgR was found in both the premenopausal as well as the post­
menopausal patients although admittedly the number of patients in the 
l a t t e r group was too small to draw f i rm conclusions. 
Fig. 3 shows the estimated RFS for the premenopausal patients. In the 
upper panel, i t is c l e a r l y shown that in the CMF-treated group of patients 
those with PgR +ve tumors had a s i g n i f i c a n t l y longer RFS than those with 
PgR -ve tumors (p<0.02; p*=0.02). On the other hand, in the non-adjuvant 
treated group of premenopausal patients with comparable tumor stages, PgR 
lacked prognostic signif icance (F ig. 3 lower panel, p>0.1; p*=0.1). I t can 
be read from the Figure that the CMF treatment may have some benefit in 
the PgR +ve group of patients but does not favourably affect the course of 
the disease in PgR -ve pat ients. 
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Λ PgR. η=4θ г :10 I 
PgR- η -- 13 г= 6 I 
premenopausal poor prognosis 
NO ADJUVANT 
p> 0 1 
64 108 132 
t ime ( months ) 
FIG. 3. Estimated RFS and the PgR-status of the tumor in the group of 
CMF-treated premenopausal patients (upper panel) and of the non-adjuvant, 
"poor prognosis", premenopausal patients (lower panel). 
MULTIVARIATE ANALYSIS 
The interactions between the prognostic variables were studied with Cox's 
mult ivar iate analysis. The results are outl ined in Table 4. In the whole 
study group of 350 pat ients, the prognosis var iable, especial ly the lymph 
node status, had the highest prognostic power (p<0.00001). The size of the 
primary timor and the q u a l i t a t i v e PgR-status of the tumor increased the 
p r e d i c t a b i l i t y of the recurrence rates (p<0.003). Al l other factors lacked 
s i g n i f i c a n t prognostic information. Neither the type of surgical treatment 
nor the i n s t i t u t i o n of adjuvant radiotherapy nor the i n s t i t u t i o n of adju­
vant chemotherapy s i g n i f i c a n t l y affected the RFS. In the presentation of 
the results in Table 4, these factors were combined in the variable " p r i -
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тагу treatment". Consistent with our f indings in the univariate analysis, 
PgR lacked prognostic power when only considering the group of non-adju­
vant treated pat ients. In t h i s group of patients the prognosis var iable, 
especial ly the lymph-node status, proved to be the only s igni f icant pre­
d i c t i v e factor . 
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n.s.=not s i g n i f i c a n t 
Neither in the premenopausal nor in the postmenopausal subgroup of pa­
t i e n t s the PgR-status reached s t a t i s t i c a l l y s ign i f icant prognostic value 
(data not shown). The resul ts in the CMF-treated group of patients were 
quite d i f f e r e n t . In accordance with the outcome of the univariate analy­
s i s , the q u a l i t a t i v e PgR-status proved to be a highly s igni f icant prognos­
t i c factor (p<0.0001). The quantitat ive PgR data were of only minor sta­
t i s t i c a l signif icance in the prediction of the RFS. Besides the PqR-sta-
t u s , the menopausal state and the lymph-node state were the only s i g n i f i ­
cant discriminants (p<0.002). The premenopausal patients with PgR +ve 
tumors were expected to have a better prognosis than those with PgR -ve 
tumors. In the postmenopausal subgroup, the number of patients was too 
small to permit a r e l i a b l e analysis separately. 
DISCUSSION 
The present data c l e a r l y show that PgR has no prognostic signif icance with 
regard to the r i s k of recurrence in patients with primary breast cancer 
87 
who did not receive adjuvant chemotherapy. Our resul ts obtained in a 
rather large number of patients after a median observation period of more 
than 5 years, did not change when the tumor stage or menopausal state were 
taken into account. In the group of patients treated with adjuvant chemo-
therapy, the premenopausal PgR +ve patients had a s ign i f i can t l y lower r isk 
of recurrence and a longer RFS than the PgR -ve pat ients. In addit ion, in 
the adjuvant CMF-treated pat ients, those with the higher PgR levels had a 
more favourable prognosis than those with the lower PgR concentrations in 
the i r tumors. 
These results were obtained from both univariate as well as mult ivar iate 
analyses. The obvious advantage of mul t ivar iate analysis is the a b i l i t y to 
examine interactions between prognostic var iables. This implicates that 
i f a factor proves to have prognostic s igni f icance, a change in the value 
of the factor in question affects the RFS i f a l l other factors are kept 
constant. Therefore, i t is unl ikely that imbalances in c l i n i ca l character-
i s t i cs have biased our data. 
With regard to the CMF-treated pat ients, more premenopausal women were 
found in the PgR +ve group compared with the PgR -ve ones. In the uni-
var iate analysis both in premenopausal as well as in postmenopausal pa-
t ien ts the high prognostic signif icance of PgR persisted (for postmenopau-
sal patients data not shown). Given the small numbers of patients in these 
subgroups, imbalances in c l i n i ca l character is t ics are l i k e l y to occur. 
Indeed, the resul ts of the mult ivar iate analysis indicated that the pro-
gnostic signif icance of PgR was confined to the premenopausal group of 
pat ients. 
Our f indings could, at least in par t , explain the lack of consensus on 
the prognostic signif icance of PgR. Table 5 summarizes the l i t e ra tu re 
data. With regard to the studies excluding al l patients who received sys-
temic adjuvant therapies (Table 5A), none of the ci ted authors found a 
prognostic signif icance for PgR, in keeping with our data. Table 5B shows 
that in the studies including various numbers of patients receiving adju-
vant chemotherapy, PgR predicted the r isk of recurrence in some of these. 
When only those patients are regarded who received adjuvant chemotherapy, 
Fisher et al (26) found a minor s ign i f icant predict ive value for PgR and 
Howell et al (27) found a highly s ign i f icant dif ference in the RFS only in 
premenopausal women, in accordance with the present data. The other c i ted 
studies included patients who received adjuvant endocrine therapies. 
In terest ing ly , the observed differences in the RFS between the adjuvant 
CMF-treated PgR +ve and PgR -ve patients seem to be the resul t of the 
somewhat better prognosis for the former and the rather poor result of 
chemotherapy in the l a t t e r . Admittedly, those observations have to be 
interpreted with caution because of the study protocol but nevertheless 
they are in keeping with the results of Clark et al (2 ) . In their report 
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TABLE 5. REVIEW OF LITERATURE DATA ON THE PROGNOSTIC SIGNIFICANCE OF PgR. 
Author ( re f ) 
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Abbreviations: pre=premenopausal; post=postmenopausal; chemo=chemotherapy; 
horm=hormonal therapy; n.s.=not s ign i f icant 
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on the prognostic signif icance of PgR in adjuvant-treated stage I I breast 
cancer pat ients, the PgR -ve group had a very similar poor prognosis with 
only 50% of the patients expected to be relapse-free after 2 - 2 . 5 years 
of observation. Howell et al (27,30) demonstrated in the i r cont ro l led, 
prospective, randomised t r i a l that only premenopausal PgR +ve patients 
experienced a benefit from adjuvant CMF and had a s ign i f i can t l y longer RFS 
than the PgR -ve group of patients. The same authors stated in an ear l ier 
study (3) that PgR was of no prognostic signif icance in patients not 
treated with adjuvant CMF. 
There is no ready explanation for the f inding that a marker of hormonal 
responsiveness, as PgR i s , would be useful as a predictor of the outcome 
of adjuvant chemotherapy. In l i t e ra tu re , there is considerable controversy 
as to what extent the beneficial effects of adjuvant chemotherapy are 
merely accounted for by changes in the endocrine environment of the t u -
mor. The induction of a chemical castration by the chemotherapy could be 
held responsible for the observed beneficial ef fects of adjuvant CMF in 
PgR +ve (endocrine responsive) patients as suggested by Howell et al 
(27,30). The data from the Milan t r i a l s of Bonadonna et al (29) do not 
support th is theory. The present data favour the hypothesis of endocrine 
mediated ef fects of adjuvant chemotherapy. 
As was established ear l ier for ER (5) , in non-adjuvant treated patients 
PgR has no prognostic signif icance with regard to the r isk of recurrence 
or the RFS, independently of the tumor stage or the menopausal state. In 
premenopausal adjuvant CMF-treated patients those with PgR +ve tumors have 
a s ign i f i can t l y lower r isk of recurrence and a longer estimated RFS than 
those with PgR -ve tumors. The present data urge the need of a reappraisal 
of the prognostic signif icance of PgR and of the mechanism of action of 
adjuvant chemotherapy. 
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Comment on chapter 6 
In the period between submission and acceptation for publ icat ion of t h i s 
study, Padmanabhan et a l . published a report in the Lancet (1) on the 
mechanisms of action of adjuvant chemotherapy in early breast cancer. The 
authors studied in a large prospective randomized control led t r i a l the 
outcome of adjuvant chemotherapy consisting of the combination of cyclo-
phosphanide, methotrexate and f l u o r o u r a c i l (CMF). Premenopausal patients 
who were treated with CMF had a s i g n i f i c a n t l y longer relapse-free survival 
than those who did not receive such treatment (median observation period 
38 months). Upon further analysis, i t became evident that patients with 
CMF-induced amenorrhoea had s i g n i f i c a n t l y longer relapse-free as well as 
overall survival times than controls. In contrast, a similar benefit of 
adjuvant CMF was not established in the CMF-treated group of patients who 
did not become amenorrhoeic. Apart from the prognostic signif icance of the 
CMF-induced amenorrhoea, the authors demonstrated that only the premeno­
pausal patients with PgR +ve tumors s i g n i f i c a n t l y benefited from the adju­
vant chemotherapeutic regimen in terms of both the re l apse-free as well as 
the overall survival times. Premenopausal patients with PgR -ve tumors 
f a i l e d to benefit from the adjuvant chemotherapy. In postmenopausal pa­
t i e n t s , adjuvant CMF lacked any benefit regardless of the PgR-status of 
the tumor. The authors concluded that t h e i r data strongly support the 
hypothesis that adjuvant chemotherapy acts pr imar i ly through an endocrine 
effect secondary to ovarian ablation induced by the chemotherapeutic mode 
of treatment. 
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The resul ts of our studies, presented in Chapters 3, 4 and 6, support 
and extend the f indings of Padmanabhan et a l . Therefore, we wrote the f o l ­
lowing "Letter to the Editor" (Lancet i i , 861, 1986): 
" S i r , Dr.Padmanabhan and colleagues (Aug 23, ρ 411) suggest that adjuvant 
chemotherapy with cyclophosphanide, methotrexate, and f l u o r o u r a c i l (CMF) 
in early beast cancer exerts i t s beneficial ef fects mainly by ovarian sup­
pression in premenopausal women. Their conclusions are based upon t h e i r 
f indings of longer relapse-free and overall survival both in patients with 
CMF-inducd amenorrhoea, compared with patients without cessation of menses 
and with contro ls , and in CMF-treated premenopausal progesterone receptor 
(PR) posit ive pat ients, compared with controls. Fig 2A-D and table I I of 
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the i r report suggest that PR status was of no prognostic signif icance in 
contro ls . 
Our data (1) on the prognostic signif icance of the PR status in early 
breast cancer, in 350 patients seen at one centre, support the f indings of 
Padmanabhan et a l . We found (updated f igures) that in 261 patients who re-
ceived no systemic adjuvant treatment, PR status had no prognostic s ign i -
ficance with regard to relapse-free survival after a median observation 
period of 69 months independently of menopausal state and tumour stage. In 
contrast, in the 89 pat ients treated with adjuvant CMF those with PR posi-
t i ve tumours had s ign i f i can t l y longer relapse-free survival than those 
with PR negative tumours (p=<0.0001). 
These data indicate that the PR status is a powerful predictor of the 
outcome of adjuvant chemotherapy. I f the benef ic ial effects of adjuvant 
CMF are accounted for by ovarian suppression, one would expect steroid-
hormone receptor ac t i v i t i e s to have predict ive value. The f inding that PR 
rather than estrogen receptor status had such important prognostic s ign i -
ficance accords with our data in advanced breast cancer: PR proved to be a 
highly s ign i f icant predictor of the outcome of endocrine therapy only when 
PR was analysed immediately before the star t of such treatment (2) . In the 
study of Padmanabhan and colleagues PR was always assessed short ly before 
the star t of the adjuvant chemotherapy and thus CMF-induced ovarian sup-
pression. 
Before drawing f i rm conclusions on the mechanism of action of adjuvant 
chemotherapy we need to know whether premenopausal PR posit ive patients 
who become amenorrhoeic during CMF treatment have longer relapse-free sur-
vival than those who do not. I f so, one might expect premenopausal PR po-
s i t i ve controls who become amenorrhoeic spontaneously in the relapse-free 
interval to have longer relapse-free survivals than those who remain pre-
menopausal ." 
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Steroid receptor - status and hormonal responsiveness 
The breast is a target tissue for estradiol and progesterone. In hunan 
breast cancer the responsiveness of the tumor to hormones is ref lected in 
objective remissions achieved with such therapy. "Rie hormonal responsive-
ness, present in about one th i rd of the patients with metastatic breast 
cancer, correlates well with the estrogen receptor status of the tumor as 
determined by biochemical assays. I t is now generally accepted that about 
50% of the patients with ER +ve tumors achieve an objective remission on 
hormonal treatment modalities whereas those with ER -ve tumors rare ly res-
pond (1 ,2 ,3) . As far as the progesterone receptor status is concerned, 
Chapter 4 reports on i t s predict ive value in a group of 84 patients with 
ER +ve advanced breast cancer. In th is group of patients who a l l received 
hormonal therapy as the i r f i r s t systemic treatment, 60% of the patients 
with PgR +ve tumors and about 30% of the patients with PgR -ve ttinors 
achieved an objective remission. In the same study period, 15 patients 
with ER -ve tumors - not included in the study of Chapter 4 - also receiv-
ed hormonal treatment as thei r f i r s t systemic therapy. Six of these pa-
t ients had a PgR +ve tumor and 9 a PgR -ve tumor. None of the patients 
with ER -ve PgR -ve tumors and 2 out of the 6 patients with ER -ve PgR +ve 
tumors responded with an objective remission. TTiese resul ts as well as 
l i t e ra tu re data, suggest that hormonal responsiveness can be better pre-
dicted by adding measurement of PgR to that of ER. However, the connection 
between PgR-negativity and hormonal unresponsiveness is far from perfect. 
I t is known for long that hormonal responsiveness of breast cancer de-
creases in the course of the disease presumably due to the selection of 
dedif ferent iated ce l ls in the process of the eradication of the hormone-
dependent clones (4,5) . I t is of note that there is considerable evidence 
that breast cancer timor tissue contains a mixture of receptor +ve and -ve 
ce l l s (4-8). Therefore, i t is tempting to speculate that the process of 
ded i f ferent i ation w i l l f ind i t s expression in the steroid receptor a c t i v i -
t i es in the course of the disease and possibly in the i r c l i n i ca l useful-
ness. The resul ts of the studies presented in th i s thes is , w i l l be d is -
cussed in view of the progress of the tumor to autonomy. 
As mentioned above, the resul ts of our study presented in Chapter 4 , 
indicate that the p red ic tab i l i t y of hormonal responsiveness is enhanced by 
analysing the PgR-status in patients with ER +ve tunors but that the num-
ber of fa i lu res is s t i l l considerable. However, when considering only 
those patients whose PgR-status is assessed on timor tissue obtained imme-
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diate ly pr ior to the s tar t of the hormonal treatment, i t appears that 78% 
of the patients with PqR +ve tumors achieve an objective remission compar-
ed to only 22% responders in the group of patients with PgR -ve tumors. 
When the PgR-status is analysed more than 6 months before the star t of 
treatment, no difference is found in the response rates between the pa-
t ients with PgR +ve and those with PgR -ve tumors. We, therefore, conclude 
that the predict ive value of the PgR-status is dependent on the timing of 
the biopsy for receptor analysis. Remarkably, a similar timing dependent 
re lat ionship was not demonstrated with regard to the ER-status. The data 
suggest that notably the PgR-status is l iab le to changes in the course of 
the disease. Support for th is suggestion is found in Chapter 3. In that 
study we have analysed both the ER- as well as the PgR-status of the tumor 
sequential ly in the course of the disease in individual pat ients. The data 
c lear ly show that there is a considerable v a r i a b i l i t y in the PgR-status on 
sequential biopsies and to a lesser degree in the ER-status: the PgR-sta-
tus of the tumor changed in 28% on subsequent biopsy and the ER-status in 
18% of the cases. The higher discordance rate in the PgR-status is almost 
exclusively a t t r ibutab le to the loss of PgR-activity: 43% of the i n i t i a l l y 
PgR +ve tuiiors became PgR -ve on subsequent biopsy later in the course of 
the disease whereas only 19% of the tumors lost i t s ER +ve status. Recent-
l y , we updated these findings and very similar resul ts were obtained. At 
present, both receptor ac t i v i t i es have been analyzed sequentially in the 
course of the disease in 64 patients with advanced breast cancer. The d is-
cordance rate in the PgR-status is 33% whereas only 18% of the analyses 
give discordant resul ts in the ER-status. The PgR +ve tumors changed to 
PgR -ve in 45% of the tumors (15 out of 33) compared to 12% change from ER 
+ve to ER -ve (5 out of 40) (p<0.05). These f indings i l l u s t r a t e the de-
crease in hormonal responsiveness of breast cancer in the course of the 
disease as far as ref lected in the steroid receptor status. The study on 
the d i s t r i bu t ion of the receptor phenotypes in the successive stages of 
the disease in d i f fe rent patients (Chapter 2) once more demonstrates the 
decrease in the frequency of receptor +ve tumors with advancing disease. 
The receptor phenotype ER +ve PgR +ve, which is most t i g h t l y related to 
hormonal responsiveness, occurs in 71% of the patients with the ear l iest 
detectable stage of the disease, i . e . , those with non-palpable, operable 
primary breast cancer. With advancing disease, the frequency of the ER +ve 
PgR +ve tumors gradually decreases to 41% at the time of the appearance of 
the f i r s t metastases. At even more advanced stages, only 28% of the tunors 
had retained detectable levels of both receptor a c t i v i t i e s . In keeping 
with the data on sequential biopsies, the decrease in the incidence of PgR 
p o s i t i v i t y was c lear ly more pronounced than the decline in ER-posi t iv i ty. 
Consequently, the PgR-status is only useful when the biopsy is taken imme-
d ia te ly before the s tar t of treatment. 
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Steroid receptor - status and prognosis 
I t is generally accepted that patients with hormonal responsive breast 
cancer have a more favourable prognosis than those with hormone unrespon-
sive tumors. Accordingly, the ER-status of the primary tumor, r e l a t i ve l y 
stable in the course of the disease and s ign i f i can t l y related to the hor-
monal responsiveness of the tumor, provides prognostic information with 
regard to the overall survival time (1,2) . In the late seventies, several 
studies indicated that patients with ER +ve primary breast cancer are ex-
pected not only to survive for a highly s ign i f i can t l y longer period than 
those with ER -ve tumors but moreover appear to have a s ign i f i can t l y lower 
r isk of developing metastatic disease irrespect ive of other prognostic 
variables. From a short-term follow-up study, reported in Chapter 5 . 1 , we 
drew a similar conclusion. However, in a malignancy in which metastases 
may appear even as late as 15 to 20 years after the i n i t i a l diagnosis, 
conclusions on the signif icance of prognostic factors should not be 
drawn when based upon short-term follow-up studies. This statement is 
strongly supported by our more recent analysis in Chapter 5.2 which showed 
that after a re l a t i ve l y long-term observation period in the same pat ients, 
the ear l ier reported lower r isk of recurrence in the group of patients 
with ER +ve tumors was no longer found. 
Anyhow, patients with ER +ve tumors do have a d i f fe rent course of the d i s -
ease than those with ER -ve tumors: when considering only those patients 
who developed metastases during the observation period, the patients with 
ER +ve tunors relapsed after a s ign i f i can t l y longer period than those with 
ER -ve tumors (37 vs. 20 months respect ively) . We, therefore, concluded 
that the ER-status of the primary tumor does not provide information on 
the l ikel ihood but rather re f lec ts the timing of the occurrence of meta-
stases. 
With regard to the prognostic signif icance of the PgR-status, the l i t e r a -
ture is less p r o l i f i c (Chapter 6 ) . The interpretat ion of the resul ts might 
be jeopardized by the fact that increasing numbers of pat ients, who, in 
recent years, received either hormonal or chemotherapeutic adjuvant thera-
pies, are included in these studies. In Chapter 6, we reported that a 
similar conclusion as ear l ier reached for the ER-status, holds true for 
the PgR-status: in the group of patients who did not receive adjuvant sys-
temic treatment, the r isk of recurrence did not d i f f e r s ign i f i can t l y be-
tween the patients with PgR +ve and PgR -ve tumors. The resul ts of the 
analysis in the group of patients who received adjuvant chemotherapy, were 
quite d i f f e ren t . In th is group of pat ients , the premenopausal women with 
PgR +ve tunors had a s ign i f i can t l y lower r isk of recurrence and a longer 
relapse - free survival than those with PgR -ve tumors at least in r e l a t i -
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vely short-term fol low-up. The challenging question arises why a marker of 
hormonal responsiveness as PgR i s , would predict the outcome of adjuvant 
chèmotherapeutic modalit ies of treatment. This rather unexpected f inding 
could at least in part be explained by the endocrine effects of adjuvant 
chemotherapy which have recently received renewed attention as discussed 
in the comment on Chapter 6. I f the beneficial ef fects of adjuvant chemo-
therapy were indeed par t ly accounted for by inducing a chemical castrat ion 
in premenopausal women, the prognostic signif icance of the PgR-status is 
not too unexpected in view of our ear l ier f indings on the predict ive value 
of PgR with regard to hormonal responsiveness. Recently, Beex et al de-
monstrated in a report from th is i n s t i t u t e , that the dominating prognostic 
factors with regard to prolongation of the relapse-free survival time in 
adjuvant chemotherapy-treated premenopausal patients were: a PgR +ve 
tumor, the occurrence of a persistent amenorrhea during the chemotherapy 
and age over 40 at f i r s t diagnosis (9) . These prognostic factors were 
ident i f ied by using a stepwise proportional hazards regression analysis. 
We therefore conclude that the mechanisms of action of adjuvant chemothe-
rapy are in need of serious reappraisal. Before advocating adjuvant che-
motherapy as a standard treatment for premenopausal patients with lymph-
node posit ive primary breast cancer (10,11), the patients who w i l l actual-
ly benefit from th is type of treatment should be ident i f ied more r e l i a -
bly. Moreover, the benefi t of adjuvant chemotherapy, i f any, has to be 
compared to the potential benefits of adjuvant hormonal therapy in subsets 
of patients who are comparable in the main prognostic factors, including 
the steroid-receptor status. Studies of th i s type have never been report-
ed. 
With regard to the p red ic tab i l i t y of the post-relapse survival t ime, 
there is general agreement on the prognostic power of the ER-status of the 
tumor. There is no consensus on the prognostic signif icance of the PgR-
status in th i s respect (12,13,14,15). One of the factors which may account 
for the controversial resul ts in the l i t e r a t u r e , might be the considerable 
loss of PgR ac t i v i t y in the course of the disease which undermines the 
c l i n i ca l usefulness of the analysis in a biopsy taken early in the course 
of the disease. The survival curves depicted in Fig. 1 , i l l u s t r a t e th i s 
statement. The PgR-status as assessed in the tissue of the primary tumor 
has no prognostic signif icance with regard to the post-relapse survival 
(p>0.1). On the other hand, when the PgR-status is assessed in tumor t i s -
sue obtained from the f i r s t metastatic s i t e , the patients with PgR +ve 
tumors have a s ign i f i can t l y longer post-relapse survival than those with 
PgR -ve tumors (p=0.005). These curves are based upon the follow-up data 
of 119 patients with advanced breast cancer who were a l l treated in our 
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FIG. 1. Estimated post-relapse survival times related to the PgR-status 
of the tumor. In the l e f t panel the PgR-status was assessed in the primary 
tumor; in the r i g h t panel in tumor t issue from the f i r s t metastatic s i te 
(n=number of pat ients; Τ =number of deaths; p-value by the log-rank-test) . 
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FIG. 2. Estimated post-relapse survival times related to the ER-status of 
the tumor. In the l e f t panel the ER-status was assessed in the primary 
tunor; in the r i g h t panel in tunor tissue from the f i r s t metastatic s i t e . 
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center between 1976 and 1986. It should be stressed that none of the pa­
t i e n t s received any adjuvant systemic treatment in the past. I t is of note 
that in t h i s group of patients the ER-status does reta in i t s highly s ign i­
f icant prognostic power irrespective of the timing of the biopsy for re­
ceptor analysis, as shown in Fig. 2. 
Figure 3 shows the overall survival curves related to the ER- and PgR-sta­
tus of the primary tumor. In the r i g h t panel, the prognostic significance 
of the ER-status is reconfirmed, i . e . , the longer overall survival time 
occurring in patients with ER +ve tumors. In the l e f t panel, i t is shown 
that the PgR-status of the primary tumor does not s i g n i f i c a n t l y predict 
the overal l survival time. 
7o Overall survival 
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FIG. 3. Estimated overall survival times of the patients whose receptor 
status was assessed in the primary tumor. 
Apparently, the PgR-status of the primary tumor does not re l iab ly predict 
the frequently protracted course of breast cancer. The considerable var ia-
b i l i t y of the PgR-status in the course of the disease may account for th i s 
lack of prognostic signi f icance. The re l a t i ve l y stable ER-status provides 
more re l i ab le prognostic information with regard to the overall survival 
times. 
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Reeds in 1979 werd o.a. door Beex (1) melding gemaakt van een serie waar-
nemingen welke deed vermoeden dat het meten van de recep to r -ac t i v i te i t 
voor progesteron (PgR) naast die voor estradiol (ER) in het tumorweefsel 
van patiënten met een gemetastaseerd mairniacarcinoom, van belang kan z i j n 
b i j de keuze van behandeling. De progesteron receptor is een specif iek 
eindprodukt van stimulering van de doelwitcel door es t rad io l . De aanwezig-
heid van PgR zou wijzen op een intakt mechanisme van deze stimulering door 
oestrogenen en, dientengevolge, op hormoongevoel igheid van de tumor (2) . 
In d i t proefschr i f t worden de resultaten beschreven van een studie over de 
betekenis van PgR om deze hormoongevoel igheid te voorspellen. Tevens wor-
den gegevens verstrekt over de kans op het ontwikkelen van metastasen, 
over de duur van de z iek tevr i je periode en over de levensverwachting van 
patiënten b i j wie in het primaire carcinoom zowel ER als PgR konden worden 
gemeten. 
Het is reeds lang bekend dat ongeveer 50% van de patiënten met een ER 
pos i t ie f gemetastaseerd mammae arc inoom toch niet gunstig reageert op hor-
monale behandelwijzen. In Hoofdstuk 1 worden enkele factoren die h i e rb i j 
een rol zouden kunnen spelen, in het kort vermeld. 
In Hoofdstuk 2 worden gegevens verstrekt over het vóórkomen van de ver-
schil lende "receptor-phenotypen" b i j patiënten met een primair mammacar-
cinoom. Bi j ruim 60% van deze patiënten bleek PgR a c t i v i t e i t in het tumor-
weefsel aantoonbaar en de meesten van deze patiënten, 201 van de 233, 
waren ook ER pos i t ie f . Na de menopauze werden vaker ER positieve tumoren 
gevonden dan daarvoor t e r w i j l voor PgR het omgekeerde gold. 
Het v ie l op dat er geen re la t i e werd gevonden tussen de uitgebreidheid van 
de z iekte, uitgedrukt in de door ons aangepaste TN-c lass i f ica t ie , en de 
frekwentie van de verschil lende receptor phenotypen. Wel werden versch i l -
len gevonden in deze frekwenties in de opeenvolgende stadia van de ziek-
te . In het vroegste stadium waarin het primaire mammae are inoom wel door 
middel van mammografisch onderzoek herkend maar nog niet gevoeld kon wor-
den, bleek de tumor b i j 79% van de patiënten PgR pos i t ie f (zie ook het 
proefschr i f t van J.G.M. Tinnemans, 1986, KU Nijmegen). In het stadium 
waarin de tumor wél palpabel was en curatieve chirurgische behandeling nog 
mogeli jk, bleek 64% van de tumoren PgR-positief. Was er reeds ingroei in 
de thoraxwand of waren er uitzaaiingen in de in f rac lav icu la i re lymfekl ie-
ren, dan bleek d i t percentage gedaald to t 59. In de eerste métastase op 
afstand bleek de frekwentie van PgR-positief tumorweefsel 41%. Tenslotte 
bleek in de groep patiënten met ver gevorderde ziekte slechts 29% van de 
onderzochte tumorweefsels PgR-positief. Deze bevindingen zouden erop kun-
nen duiden dat in het verloop van de ziekte hormoongevoel igheid verloren 
gaat. 
Steun voor d i t gegeven, verkregen u i t een "cross-sect ional" studie, 
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vindt men in Hoofdstuk 3 waarin wordt nagegaan of de receptor-status van 
de tumor ook b i j de individuele patiënte verandert gedurende het verloop 
van de z iekte. In overeenstemming met de in 1980 door Koenders e.a. (3) 
vermelde gegevens, bleek ook in onze studie dat de ER-status een r e l a t i e f 
stabiel kenmerk van het tumorweefsel i s . Daarentegen werd ongeveer de 
he l f t van de aanvankelijk PgR-positieve tumoren in het verloop van de 
ziekte negatief. B i j nadere analyse werd du ide l i j k dat naarmate de ER of 
PgR in de eerste biopsie kwant i tat ief hoger was, de tumor in een later ge-
nomen biopsie minder vaak receptor-negatief werd dan wanneer de receptor 
a c t i v i t e i t in de eerste biopsie lager u i t v i e l . 
In Hoofdstuk 4 wordt nagegaan of deze resultaten ook van kl inische be-
tekenis z i j n . In een groep patiënten met een ER-positief gemetastaseerd 
mammae arc inoom die als eerste systeembehandeling hormonale therapie kre-
gen, bleken de vrouwen met PgR-positief tumorweefsel veel vaker in remis-
sie te komen dan z i j met een PgR-negatieve tumor: 60% ten opzichte van 
31%. Speciale aandacht werd geschonken aan het t i j ds in te rva l tussen de 
datum van de biopsie en de datum van de star t van de behandeling. Daarbij 
bleek het percentage objectieve remissies b i j een korte duur van d i t 
interval te st i jgen to t b i jna 80 b i j de patiënten met een PgR-positieve 
tumor, t e r w i j l d i t b i j degenen met een PgR-negatieve tumor onder deze 
omstandigheden slechts ongeveer 20% was. Bedroeg het interval meer dan een 
half j aa r , dan was het percentage objectieve remissies in beide groepen 
ongeveer g e l i j k . Tenslotte bleek dat wanneer de PgR a c t i v i t e i t groter was 
dan 100 fmol/mg e i w i t , hormonale therapie succesvol was b i j zelfs meer dan 
80% van de betreffende patiënten. Hieraan moet overigens worden toegevoegd 
dat b i j afwezigheid van PgR a c t i v i t e i t toch nog 31% van deze patiënten met 
een ER-positieve tumor, ook in remissie kwam. Het kenmerk PgR a c t i v i t e i t 
van een tumor informeert beter over hormoongevoel igheid maar is minder 
specifiek dan het kenmerk ER. Men kan zeggen dat PgR beter hormoongevoe-
1 igheid aangeeft, t e rw i j l ER nauwkeuriger informeert over ongevoeligheid 
voor hormonale behandelwijzen. 
Men moet zich na tuur l i j k afvragen of de ER- en de PgR-status ook van be-
lang is om het z iek tevr i je interval en de u i te inde l i j ke levensverwachting 
te voorspellen. In Hoofdstuk 5.1 wordt gesuggereerd dat patiënten met een 
ER-positieve primaire tumor een s igni f icant kleiner r i s i co van rec id ie f 
hebben dan de vrouwen met een ER-negatieve tumor. Deze resultaten werden 
verkregen na een r e l a t i e f korte observatie-periode met een mediane duur 
van 34 maanden. Het bleek dat d i t gold voor vrouwen zonder en voor vrouwen 
met tumor posit ieve lymfekl ieren, overigens alleen na de menopauze. 
Uit de analyse van dezelfde groep patiënten na een langere observatieperi-
ode (mediane duur ruim б jaar) (hoofdstuk 5.2), moest worden geconcludeerd 
dat de kans op een r e c i d i e f voor beide groepen patiënten even groot was! 
Te zamen laten deze studies zien dat men u i ters t terughoudend moet z i j n 
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met uitspraken over de prognostische betekenis van een tumorkenmerk, i n -
dien deze gebaseerd z i j n op een betrekkel i jk korte periode van observatie. 
De beide studies u i t Hoofdstuk 5 leerden nog ie ts . De z iek tevr i je periode 
was voor de vrouwen met een ER-positieve tumor b i j wie zich metastasen 
ontwikkelden, s ign i f i cant langer dan voor de vrouwen met een ER-negatieve 
tumor. Wij menen dan ook de gevolgtrekking te mogen maken dat de ER-status 
van de primaire tumor niet zozeer informatie verschaft over het al dan 
n iet optreden van metastasen maar veel meer informeert over de groei snel-
heid van de tumor waarvan de z iek tevr i je periode immers k l in isch de duide-
l i j k s t e uitdrukking i s . 
In Hoofdstuk 6 wordt aangetoond dat ook de PgR-status ongeschikt is om 
een onderscheid te maken tussen patiënten met een hoger of lager r i s i c o 
van rec id ie f . Met nadruk wordt erop gewezen dat zowel in deze studie als 
in die van Hoofdstuk 5, patiënten die adjuvante chemotherapie kregen, n iet 
in de analyse werden betrokken. De overige resultaten van Hoofdstuk 6 
tonen aan dat d i t gegeven niet zonder betekenis i s . Beschouwt men immers 
alleen die patiënten die wèl behandeld werden met adjuvante chemotherapie, 
dan bleken premenopauzaie patiënten met een PgR-positieve tumor wel dege-
l i j k een kleinere kans op een rec id ief te hebben dan de vrouwen met een 
PqR-negatieve tumor. Met nadruk voegen wi j hier aan toe dat deze resul ta-
ten werden verkregen in een studie met een betrekkel i jk korte observatie-
periode en daarom met de nodige reserve bekeken dienen te worden. Zouden 
ze overigens na een langere follow-up bevestigd worden, dan zou deze waar-
neming een bijdrage kunnen leveren aan de opheldering van de nog steeds 
bestaande controverse over het werkingsmechanisme van adjuvante chemo-
therapie. Zoals in het commentaar op Hoofstuk 6 beschreven, groeit het 
aantal aanwijzingen dat het nut van adjuvante chemotherapie b i j het p r i -
maire mammae are i η oom zeker voor een deel toe te schrijven is aan de endo­
criene effecten van deze behandeling. Z i j veroorzaakt immers vaak u i t v a l 
van de ovariële funct ie b i j premenopauzaie vrouwen. Wij hechten eraan te 
stel len dat er nog besl is t onvoldoende argumenten z i j n om adjuvante chemo-
therapie te adviseren als standaardbehandeling voor premenopauzaie pat iën-
ten met een primair mammae arc inoom en oksel kl iermetastasen. 
Uit de gegevens van Hoofdstuk 7 b l i j k t dat de aanzienl i jke v a r i a b i l i t e i t 
van de PgR-status in het beloop van de z iekte, er waarschi jn l i jk de oor-
zaak van is dat men m.b.v. de PgR-status van de primaire tumor de levens-
verwachting van de patiënten niet kan schatten. Wel kon worden aangetoond 
dat patiënten wier eerste métastase PgR-positief bleek, langer overleefden 
dan patiënten met PgR-negatieve metastasen. Overigens wordt er hier op ge-
wezen dat b i j de beoordeling van de prognostische betekenis van kenmerken 
als ER en PgR de resultaten van de toegepaste behandelwijzen betrokken 
moeten worden. In een in d i t proefschr i f t n iet verwerkte studie werd met 
behulp van een mul t ivar iant ie analyse van gegevens van 119 patiënten met 
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een gemetastaseerd mammacarcinoom nagegaan welke betekenis het tenminste 
éénmaal bereiken van een objectieve remissie t i jdens welke behandeling dan 
ook, heeft voor de schatting van de levensverwachting. Daarbij bleek dat 
het bereiken van minimaal één objectieve remissie als factor voor een be-
tere prognose van grotere betekenis is dan welk to t nu toe aanvaard ken-
merk dan ook, inclusief ER en PgR! 
Niettemin l u id t onze conclusie dat het aanbeveling verdient om in tunor-
weefsel van patiënten met een marmiacarcinoom de receptor -ac t i v i te i t voor 
estradiol en progesteron, zowel kwal i ta t ie f als kwant i ta t ie f , te meten. Te 
zamen met kl in ische gegevens z i jn z i j immers van nut om dat behandelings-
plan te kiezen dat, met de minste kans op schade door bijwerkingen, l e id t 
to t een maximaal aantal objectieve remissies. Daarbij geldt voor de PgR-
status met name dat herhaalde metingen in de opeenvolgende stadia van de 
ziekte wel noodzakelijk z i j n voor het grootste rendement. Het kenmerk ER 
zegt, indien negatief, meer over hormoonongevoeligheid; het kenmerk PgR, 
indien pos i t i e f , meer over hormoongevoeligheid. Voortgezet onderzoek zal 
wel l icht leren dat de PgR-status ook van belang is voor een betere ind i -
ca t ies te l l i ng van adjuvante behandelingen, d i rect in aansluiting aan de 
therapie van het primaire carcinoom. 
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STELLINGEN 
1. De receptor-aktiviteit voor progesteron zegt, indien positief, meer 
over hormoon-gevoeligheid en die voor oestradiol informeert, indien ne-
gatief, beter over hormoon-ongevoeligheid van borstkanker. 
Dit proefschrift 
2. Tijdens het verloop van de ziekte wordt een eerder progesteron recep-
tor-positieve tumor in een later stadium vaker negatief dan het geval 
is voor de oestadiol receptor-status. Daarom is het resultaat van een 
enkele meting van progesteron receptor-aktiviteit in een vroeg stadium 
van borstkanker van minder waarde om de hormoongevoelighed in een later 
stadium te voorspellen dan de uitslag van oestradiol receptor-aktivi-
teit. 
Dit proefschrift 
3. Metingen van de receptor-aktiviteit voor progesteron en oestradiol le-
veren geen bijdrage aan de schatting van het risico van recidief bij pa-
tiënten met een primair mammacarcinoom. 
Dit proefschrift 
4. Conclusies over de waarde van prognostische faktoren met betrekking tot 
de (ziektevrije) overleving van patiënten met kwaadaardige ziekten 
waarvan het ziektebeloop sterk wisselend is, kunnen pas getrokken wor-
den na een lange periode van observatie. 
Dit proefschrift 
5. Het relatief gunstige resultaat van adjuvante chemotherapie bij preme-
nopauzale patiënten met een progesteron receptor-positief mammacarci-
noom is toe te schrijven aan zowel het direct cytotoxische als het se-
cundair enaocriene effect van deze behandeling. 
Beex e.a., aangeboden voor pitblikatie 
6. De opvatting dat alle lichaamscellen worden blootgesteld aan dezelfde 
concentratie van een hormoon dat zich in het bloed bevindt zoals nog 
geponeerd in de nieuwste, zevende, editie van Williams' Textbook of En-
docrinology (p.78), is onjuist. 
7. Hormonen verhouden zich tot neurotransmitters als radio tot telefo-
nie. 
8. Het atriële natriuretische peptide is een hormoon dat in de circulatie 
op zoek is naar zijn funktie. 
Februari 1987 
9. Een hoog cortisolgehalte 's morgens bij patiënten op een afdeling in-
tensieve zorg is voor de prognose quoad vitam even ongunstig als een 
lage T4-spiegel. 
Nog niet ge-publioeerde waarneming, 
B.Span e.a.j med.drs.3 
keuzevakstage 1987. 
10. Bij cataract op jonge leeftijd moet ook de diagnose ziekte van 
Steinert-Curshmann overwogen worden. 
11. De behandeling van het fenomeen van Raynaud laat de patiënt nog steeds 
in de kou staan. 
12. Het fenomeen koopavond heeft inmiddels ook zijn intrede gedaan in de 
gezondheidszorg. 
13. Van de "referees" van mijn studies heb ik meer geleerd over mijn ge-
brek aan kennis van de Engelse taal dan over hun inzicht in mijn re-
sultaten. 
14. In de klassieke bioscoop voelde ik me thuis. Nu de oude bioscoop 
plaats maakt voor een verzameling kleine knusse ruimten, vervalt voor 
de echte filmliefhebber elk motief zijn huiskamer met videofacilitei-
ten te verlaten. 
15. Voor de humor van Laurel en Hardy ga ik door dik en dun. 
J.M.M. Raemaekers 


